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ABSTRACT

IMMUNOMODULATION OF MYELOID-DERIVED SUPPRESSOR CELLS BY
PARTICULATE β-GLUCAN IN CANCER
Sabrin Albeituni
June 4, 2015

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature
myeloid cells that promote tumor progression. In this study, we investigated the effect of
dectin-1 stimulation by yeast-derived particulate β-glucan in MDSC function and
differentiation in cancer. In vivo treatment of mice bearing lewis lung carcinoma and
mammary cell carcinoma with particulate β-glucan decreased tumor weight and
splenomegaly, and reduced the accumulation of polymorphonuclear-MDSC (PMNMDSC) but not monocytic-MDSC (M-MDSC) in the spleen and tumor. In addition,
particulate β-glucan differentially modulated the function of different MDSC subsets; it
enhanced PMN-MDSC respiratory burst and apoptosis, and induced the differentiation of
M-MDSC into F4/80+CD11c+antigen-presenting cells in a dectin-1 dependent manner.
ERK1/2 phosphorylation was also required for the acquisition of APC properties in MMDSC. Moreover, M-MSDC treated with particulate β-glucan did not promote tumor
growth in vivo when inoculated with LLC subcutaneously. To evaluate the effect of
particulate β-glucan treatment in humans, patients with non-small cell lung cancer (NSCL)
were treated with particulate β-glucan for two weeks prior to any other treatment and
vii

surgical excision of the tumor. Strikingly, the frequency of CD14-HLA-DRCD11b+CD33+ MDSC decreased in the peripheral blood, and arginase-1 expression
significantly decreased in a cohort of 15 patients. This study was the first to assess the
effect of particulate β-glucan on MDSC in lung cancer patients, towards a future inclusion
of particulate β-glucan in combination therapies in the treatment lung cancer.
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INTRODUCTION1

In every battle there comes a time when both
sides consider themselves beaten,
then he who continues the attack wins.
Ulysses S. Grant

The battle analogy is commonly used when describing the immune system in action. From
DNA restriction, surface exclusion and CRISPs systems (clustered, regularly interspaced
short palindromic repeats) in bacteria and archea (1, 2) to a highly specialized immune
system in mammals, the immune system has evolved to fulfill one role: elimination of
foreign antigens. The immune system in general is described to have two forms: innate and
adaptive. Historically, these terms used to suit the idea that an immune cell can either
respond to a foreign antigen in a rapid and non-specific fashion (i.e. innate) or adapt to the
recognition of a certain antigen, by generating memory, in a highly selective process where
these cells respond faster and more robustly after a recall of the same antigen (i.e. adaptive).

1

Part of the work in this thesis has been published in the following: Cancer J. 2013;19:490-501.
PMID:24270348 and Anti-cancer Agents Med Chem. 2013;13:689-98. PMID:23092290.
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According to this definition, macrophages, dendritic cells, granulocytes and natural-killer
(NK) cells are categorized under ‘innate immunity’, whereas T cells and B cells are
considered ‘adaptive’.

However, the categorization of immune cells under innate or

adaptive immune responses becomes elusive when describing γδ-T cells, B1 cells and
invariant NKT (iNKT) cells (3). Moreover, this definition becomes fuzzy after the
discovery

that

NK

cells

acquire

a

‘memory’

phenotype

in

response

to

cytomegalovirus(CMV) infection in which ‘memory’ NK cells present a higher cytolytic
and cytokine response after the second exposure to the virus, unlike naïve NK cells (4-6).
A twisted mechanism of innate memory emerges when elucidating the recognition of
pattern associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs)
expressed in innate and adaptive immune cells (7-9). The memory-like phenotype in innate
cells emerges as a function of epigenetic regulation and chromatin modifications upon the
stimulation of macrophages and monocytes with a Toll-like receptor 4 (TLR4) ligand (e.g
lipopolysaccharide LPS ) (10, 11) or a dectin-1 ligand (e.g fungal cell-wall β-glucan) (1214). Interestingly, repeated exposure of murine macrophages to LPS induce an array of
anti-inflammatory genes (non-tolerizable genes, class NT) while silencing the proinflammatory genes (tolerizable genes, class T) leading to endotoxin tolerance preventing
tissue damage (10, 11). In contrast, pre-stimulation of monocytes with Candida albicans
(a source of β-glucan), renders monocytes more responsive upon re-stimulation, inducing
what is referred to as ‘trained immunity’ (11-14). Escape from immunosurvaillance, is the
last ‘E’ of the three ‘Es” in cancer immunoediting theory that consists of three main phases:
Elimination, Equilibrium and Escape (15, 16). It has been well established that the immune
system is a key player during tumor development, playing ambivalent roles in tumor
2

elimination and tumor progression. Immune cells can recognize tumor-associated antigens
(17) and eliminate tumor cells through numerous anti-tumor mechanisms. However, during
tumor development, tumor factors in the tumor microenvironment modulate immune cells
towards a protumorigenic phenotype leading to local and/or systemic immunosuppression,
thus inducing tumor growth and establishing a suppressive niche in distant sites facilitating
tumor metastasis. This unique interaction between tumor and immune cells in the tumor
microenvironment has rendered immunotherapy a daunting task in our battle against
cancer.
The tumor microenvironment exclusively promotes the induction and expansion of
immune suppressors that ultimately inhibit effector T cell proliferation and the activation
of cytotoxic T lymphocytes (CTLs) and anti-tumor NK cells. Earlier studies have described
the presence of natural suppressors of lymphoproliferative responses with myeloid-cell
characteristics in mice and humans (18-22). The finding that suppressive monocytes
expressing CD11b/Mac-1 accumulate in the spleens of tumor-bearing mice (23), has led to
the identification of T cell suppressors that express CD11b/Mac-1 and Gr-1 antigens in the
spleens of mice immunized with highly immunogenic recombinant anti-cancer vaccines
and tumor-bearing mice (24-27). A plethora of following studies in various cancer models,
have identified these cells as a heterogeneous population of cells with myeloid origin that
has the potential to differentiate into mature granulocytes, macrophages and dendritic cells,
but under the influence of tumor factors are hampered in an immature state of
differentiation with potent immune suppressive functions. This heterogeneous population
of myeloid suppressive cells is collectively known as myeloid-derived suppressor cells
(MDSC) (28). Despite the suppressive characteristic attached to its definition, it is now
3

debatable whether tumor MDSC are suppressive during early stage of tumor development
in humans. Eruslanov et al, clearly show that tumor infiltrating neutrophils (TAN) induce
T cell responses during early stages of tumor development (29), and propose that induction
of suppression can be artificially achieved during tumor preparation in case the enzymatic
digestion cocktail sheds the TAN surface costimulatory molecules (30). Suggesting that
during the equilibrium phase, immune cells may express dual phenotypes, and depending
on how far the battle is, the equilibrium may shift towards the escape phase giving tumor
cells advantage, or being brought back to the elimination phase, that mainly is rescued upon
immunotherapy.
Heterogeneity and T cell suppression are hallmarks of MDSC biology. In mice, MDSC are
classified into two main subsets according to their morphology and markers:
CD11b+Ly6ChighLy6G- cells resemble monocytes and are called monocytic MDSC (MMDSC), and CD11b+Ly6G+Ly6C

low/int

cells with a polymorphonuclear morphology are

called granulocytic or polymorphonuclear MDSC (PMN-MDSC/PMN-MDSC) (31, 32).
The absence of a Gr-1 homologue in humans led to the inclusion of a broader spectrum of
markers in the description of suppressive myeloid cells in cancer patients. In general, MMDSC express CD14-CD33+HLA-DRlowCD11b+CD15-, while PMN-MDSC express
CD14-CD33+HLA-DRlowCD11b+CD15+ and/or CD66b+ (reviewed in ref (33)). M-MDSC
expressing Lin-CD11b+CD14+ have also been described in patients with melanoma (34).
Another adapted definition by many researchers is by defining M-MDSC in humans as
CD14+HLA-DR-/lowCD11b+CD33+ (35), It is clearly noted that the expression of a unique
marker of immunosuppression in MDSC in mice and humans has been one of the main
challenges in the field.
4

After the identification of MDSC as one of the major suppressors of T cell responses and
inducers of T cell tolerance (24, 43), numerous studies have characterized their roles in
cancer as suppressors of NK cells (44), inducers of regulatory T cells (Tregs) (45) , and
precursors of tumor-associated macrophages (39). MDSC-mediated T cell suppression is
mainly attributed to the expression of Arginase 1, iNOS, ROS (38) and cystine and cysteine
deprivation (46). A main factor responsible for the accumulation of MDSC in cancer is
the fact that MDSC are immature and do not subsequently differentiate to anti-tumor
macrophages and dendritic cells (DCs) under the influence of tumor-derived factors (33).
The fact that MDSC immune suppression can be reversed in vitro and in vivo has led to the
development of a multitude of strategies in cancer therapy.
Herein, we will discuss MDSC origin and mechanisms of immune suppression, focusing
on the therapeutic strategies targeting MDSC in tumor-bearing mice and cancer patients.
In an attempt to study a natural compound that targets MDSC with no side effects, at a
low cost and can be easily consumed by oral uptake, we studied the effect of the
immunomodulator, particulate β-glucan on MDSC in tumor-bearing animals and nonsmall cell lung cancer (NSCLC) patients. Whole glucan particles (WGP) are microparticles of 1,3-β-glucan extracted from the yeast Saccharomyces cerevisiae, that have
been shown to activate immune cells through the stimulation of C-type lectin receptor,
dectin-1 (47, 48). It is well reported that WGP treatment reduces tumor growth and
activates dendritic cells (DC), induces T cell responses and decreases the frequency of
Tregs in vivo (49). In addition, a recent report showed that WGP partially induces the
differentiation of M-MDSC to F4/80+CD11c+ cells (50). However, the role of particulate

5

β-glucan in the modulation of the function of different MDSC subsets in mice and its
implementation in the clinic needs further studies.
Herein, we delineated the effect of particulate β-glucan on the function of both PMNMDSC and M-MDSC in mice. We demonstrated that particulate β-glucan induced a
cytotoxic phenotype and subsequent apoptosis in PMN-MDSC, while converting MMDSC to potent antigen-presenting cells (APCs) that uptake, process and present
ovalbumin (OVA) Ag to OVA-specific CD4+ T cells and also cross-present Ag to prime
OVA-specific CD8+ T cells. More importantly, NSCLC patients treated with particulate
β-glucan for two weeks had a decreased accumulation of CD14- HLA-DR-CD11b+CD33+
MDSC in their peripheral blood as compared to their frequency in the peripheral blood
before treatment, which was correlated with an increased trend in peripheral T cell
activation and peripheral monocytes and MDSC Ag presentation function, and a
decreased trend in Arginase 1 mRNA expression in peripheral PMN. Overall, these
findings provide a further step in our understanding of the mechanisms of how particulate
β-glucan enhances anti-tumor immunity in mice and how that findings can be translated
in the benefit of cancer patients.
I. Implications of β-glucan treatment on immune cell responses
1. β-glucan nomenclature
β-glucans are polymers of D-glucose linked by β-glycosydic bonds. The nomenclature of
glucans varies according to the number or type of carbons that participates in the glycosidic
linkage between each two glucose monomers. In the cyclic glucose structure (Figure 1A),
the term ‘beta’ is a relative stereodescriptor in Fischer projection used to differentiate it
6

from ‘alpha’ configuration. In the beta configuration the hydroxyl group (-OH) at the
anomeric carbon 1 (C-1) is at a different side relative to the –OH group at C-5, whereas in
α-glucose the –OH groups of both carbons are at the same side (51). Glucans are also
described by the type of glycosidic linkages and branching in the glucose polymer (52).
The linkage designation of the homopolysaccharide refers to the carbons number in the Dglucose that participates in the glycosidic bond, for example, in (13)-β-D-glucan the C1 is linked to C-3 by a beta glycosidic bond (Figure 1B) (51).
2. β-glucan sources, composition, and antitumor activity
β-glucans are widely described in nature. A large variety of β-glucans have been reported
in the cell walls of different species of mushrooms, yeast, oat, barley, seaweeds, algae and
bacteria (53-60). The polymer chains of β-glucans of different sources vary in length,
glycosidic linkage configuration, the number and type of branching, the 3-dimensional
conformation, and the solubility in water and alkali solutions. Thus, variation in the
chemical composition and physical properties of β-glucans render diverse roles, either
structural or biological, in such organisms (54). In higher plants, for instance, cellulose
fibrils consists of (1,4)-β-glucan chains, whereas linear chains of (1,3)- β-glucan with (1,6)β-linked branches are the main constituents of callose, which is a polysaccharide

7

Figure 1. Representation of chemical structures of β-D-glucose (A) and (B) (1,3)-βlinked backbone with β-(1,6) branching.

8

produced in response to wounding or the synthesis of plant cell plates (59). Interestingly,
cellulose synthesis was also reported in prokaryotes such as Agrobacterium xylinum,
Agrobacterium tumefaciens, Pseudomonas, Achromobacter, Alcaligenes, Aerobacter,
Azotobacter, Rhizobium and Sarcina (61). Similarly, (1,3)-β-glucans provide structural
support to the baker’s yeast Saccharomyces cerevisiae by covalently or non-covalently
binding to the chitin in the yeast cell wall (62). β-Glucans also give a survival advantage
for virulent pathogens, facilitating the formation of cell aggregates and cell adhesion for
infection or symbiosis, and providing chemical, biological and mechanical protection (61).
Osmoregulated periplasmiic glucans (OPGs), such as cyclic (1,2)- β-glucan (CβG), are
virulence factors found in the cell walls of gram-negative bacteria (63). Arellano-Reynoso
et al, showed that in brucella bacteria, mutants deficient in CβG failed to replicate since
they were not able to prevent phagosome-lysosome fusion in host cells, and this function
was restored by treating mutants with CβG (63). In the fungal pathogen, Candida albicans,
(1,3)-β-glucans with (1,6)-β-branching were shown to have putative roles in biofilm
resistance (64). In this study, Nett et al., demonstrated that treatment of C. albicans biofilm
with (1,3)-β-glucanase rendered a lower biofilm viability in a dose-dependent manner.
Among a wide variety of polysaccharides, β-glucans have gained a particular attention in
biomedical research, due to their wide occurrence in microbes and induction of biological
activity in different animal models. Advances in genetic engineering and chemical industry
have been applied in the extraction and manufacture of different types of glucans with
altered physical properties (65). Early studies reported anti-tumor activity of β-glucans in
animal models. Fukuoka group in Japan demonstrated that lentinan extracted from the
mushroom Lentinus edodes, a popular mushroom in Japan, have a strong anti-tumor
9

activity against sarcoma 180 ascites injected subcutaneously in mice (66, 67). In this study,
two fractions of lentinan, LC-1 and LC-33, displayed anti-tumor activity when injected
intra-peritoneally 24 hours after tumor implantation in mice. The LC-1 fraction was soluble
in water and consisted mainly of (1,3) and (1,6)-β-glucan. Whereas LC-33, a linear (1,3)β-glucan, was less soluble in water and had less anti-tumor activity. Following this study,
Fukuoka group reported that chemical modification of the glucan (Pachyman) extracted
from Poria cocos impacted its anti-tumor properties (67). The linear (1,3)-β-glucan,
Pachyman, per se had no anti-tumor activity unless chemically converted, by oxidationreduction reactions, to a lentinan-like linear (1,3)-β-glucan, with a strong anti-tumor
activity in Swiss albino mice implanted with sarcoma 180 ascites. This chemical
manipulation of the structure of naturally extracted glucans, and the conversion of nonactive compounds to compounds with anti-tumor activity, emphasized the tight link
between structure of glucan and its biological functions.
In an attempt to study the anti-tumor activity of a polysaccharide with only one type of
linkage, and the effect of the length of the polymer in the tumor activity, Sasaki et al.
investigated the anti-tumor activity of a thermally-gelable (1,3)-β-D-glucan on the growth
of different tumor cell lines implanted in a Swiss albino model. This gelable glucan, is a
curdlan-type extracted from a soil bacterium mutant, Alcaligenes fecalis var. myxogenes
(IFO 13140) (68, 69). This glucan is entirely composed of (1,3)- β-linkages, and was
administered at different doses, molecular weights and at different routes to optimize the
treatment conditions. Interestingly, administration of (1,3)-β-glucan intraperitoneally with
a degree of polymerization (DPn) >50 at optimal doses showed anti-tumor effects against
sarcoma 180 cell line. The fact that the molecular weight of glucan directly impacted its
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anti-tumor activity re-emphasizes the effect of glucan supermolecular structure on its antitumor activity. Sasaki et al., also assessed the anti-tumor activity of this glucan in Ehrilch
carcinoma, NTF reticulum cell sarcoma and CCM adenocarcinoma. Although the glucan
treatment was less effective, the differences were still significant. A highly branched (1,3)β-glucan, SSG, extracted from the fungus Sclerotinia sclerotiorum also showed anti-tumor
activity on the solid-form of Sarcoma 180, but not ascites, in mice (70).
The application of glucans in cancer research, led to the development of new strategies in
bioengineering, to design new glucans with more potent applications in biomedical
research. A well-known example, is the development of whole-glucan particles (WGP) by
Jamas et al, at the Massachusetts Institute of Technology (65). WGP are microparticles
(around 2-6 microns) highly purified from the yeast Saccharomyces cerevisiae. The
method of purification consists mainly of dissolving cell-wall mannans and proteins in an
alkali solution at optimal time and temperature, while keeping the cell wall intact with
alkali insoluble glucan. The resulting glucan consists mainly of β-(1,3)-linkages with β(1,6) branches. In this method, these linkages are also chemically altered by acetic acid and
laminarase modifying β-(1,3) and β-(1,6)- linkages, respectively. WGP in biomedical
research is being applied to study its anti-tumor effects in animal models (71) and as a
drug-delivery vehicle and adjuvant (72). WGP has shown to induce the activation of
costimulatory molecules in macrophages such as CD80, CD86, MHC class II, CD40 and
CD69, the production of proinflammatory cytokines such as IL-6, TNF-α and IL-12, and
the chemokine MCP-1 (monocyte-chemotactic protein 1) in a MyD88 and Syk-dependent
signaling (73).
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WGP application in the clinic has been restricted due its insolubility in water. Therefore,
different attempts have been made to solubilize (1,3)-β-glucan. Jamas et al., at Alpha-Beta
Technology Inc., also developed new methods to produce water-soluble glucans (74).
Water- soluble glucans are referred to as PGG-glucans (poly-(1-6)-β-D-glucopyranosyl(1-3)-β-D-glucopyranose). Betafectin PGG (Alpha-Beta Technology) is prepared from
WGP by sequential treatments with acid and alkaline treatments followed by a series of
filtration and ultracentrifugation steps to obtain a non-toxic pharmaceutically applicable,
water-soluble compound at neutral pH. The same group also described other methods for
the preparation of triple-helical neutral soluble β-glucans (NSG) also derived from WGP
(75). Another extract from S. cerevisiae vastly described in the literature is Zymosan. This
extract is a crude insoluble yeast extract obtained by boiling yeast before and after trypsin
treatment, composed of polysaccharides, proteins, lipids and inorganic elements (75, 76).
Riggi and Di Luzzio demonstrated that glucan is the biologically active component of
Zymosan (76). These initial findings have driven β-glucan research to elucidate the
mechanisms by which these biological response modifiers (BRM) act in tumor-bearing
animal models to develop new therapeutic strategies in the clinic.
3. β-glucans as potent immunomodulators
The fact that β-glucans do not have any direct cytotoxic effects on tumor cells (69) led to
the hypothesis that anti-tumor effects of β-glucans are mediated by host cells. The link
between β-glucans and the immune system started to be elucidated from early studies using
zymosan. Initial studies demonstrated that zymosan induces immune response after
administration in mice, such as the increase in the phagocytic activity of macrophages (77),
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and activation of the alternative complement pathway by forming a complex with the serum
protein Properdin mediating C3 cleavage (78-85). It was not until Riggi and DiLuzio
demonstrated that (1,3)-β-glucan is the immunostimulatory agent of zymosan (76), that
implication of glucan effects in immune responses started to be investigated. In this study,
the glucan preparations from zymosan, but not lipids or mannans, stimulated an increase
in the weight of lungs and spleens of treated rats, and enhanced the phagocytic activity of
macrophages of the Aschoff’s ‘Reticuloendothelial elements’ in liver and spleen. Yeast
hydroglucan was also demonstrated by Diller et al., to cause an increase in the production
of phagocytic cells, subsequently inducing significant regression of Sarcoma 37, Sarcoma
80 and Krebs-2 carcinoma when injected intravenously in ICR/Albino mice (86).
Macrophages were the first effector cells to be described in glucan enhanced oncolytic
activity. Sherwood et al., demonstrated that glucan enhances the tumoricidal activity of
peritoneal macrophages, splenic macrophages and Kupffer cells (87). In this study
Sherwood et al., failed to express any direct effects of glucan on NK cells and T cells.
However other studies showed that the tumoricidal activity of polymorphonuclear cells
(PMN) (88) and NK cells(89) are enhanced by β-glucan. Suzuki et al., proposed that the
anti-tumor activity of lentinan, a (1,3)-β-glucan with (1,6)-β-branching, is mediated by
CD8+ cytotoxic T lymphocytes (CTL), but not CD4+ T cells or NK1.1 cells (90).
Investigating the effects of β-glucan on DC biology was relatively late compared to
macrophages, due to its relatively late discovery by Steinmann in 1973 (91). A series of
studies have been conducted to identify the receptors of β-glucans on innate immune cells.
Four β-glucan receptors have been identified; Complement Receptor 3 (CR3) also known
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as (CD11b/CD18, αMβ2-integrin, Mac-1) (92), Lactosylceramide (LacCer) (93), selected
scavenger receptors (SRs) (94) and dectin-1 (95).
4. β-glucan recognition and signaling
a) Complement Receptor 3 (CR3)
Human leukocyte complement receptor type three (CR3) was the first receptor in innate
immune cells to be described in β-glucan recognition. Ross et al., showed that unopsonized
zymosan directly binds to CR3 in human and mouse macrophages and neutrophils
enhancing their phagocytic activity and respiratory burst (96, 97). Two functional domains
have been characterized on CR3: The inserted domain (I-domain) containing the opsonic
iC3b-binding site, and a cation-independent lectin domain at the C-terminal to the I-domain
that binds to β-glucan (98, 99). Simultaneous activation of the lectin site and I-domain is
required to mediate CR3-dependent cellular cytotoxicity (CR3-DCC) against iC3bopsonized target cells (92). Vetvicka et al. demonstrated that priming of CR3 on
neutrophils or NK-cells with soluble β-glucan induces a magnesium- and protein tyrosine
kinase-dependent conformational change of the I-domain that exposes the CBRM1/5
activation epitope required for mediating phagocytosis and cytotoxic killing of iC3b-coated
tumor cells in a way that mimics phagocytosis and killing of iC3b-opsonized yeast (92).
The presence of the lectin domain in CR3, acquired this integrin the ability to signal
‘outside-in’ in addition to its ‘inside-out signaling’. This finding was further applied to
induce CR3-DCC of iC3b-coated tumor cells through the administration of soluble or
particulate (1,3)- β-glucans as adjuvant therapy in combination with anti-tumor
monoclonal antibodies (92, 100-103).
14

Soluble barley and particulate (1,3)-β-glucan (WGP) administered orally were shown to be
phagocytosed by macrophages in the gastrointestinal tract and transported to the spleen,
lymph nodes and bone marrow of tumor-bearing animals. In the bone marrow, (1,3)-βglucan undergoes further processing and degradation to smaller β-glucan fragments that
are released to bind the CR3 of granulocytes (104). Consistent with these findings, Li et al.
demonstrated that intravenously administered soluble β-glucan PGG is captured by
macrophages independent of CR3, which process and degrade PGG, releasing biologically
active soluble moieties of ~25kDa that subsequently prime CR3 on neutrophils, activate
Syk and phosphoinositol 3 kinase (PI3K) and mediate killing of iC3b opsonized tumor
cells (105). In this therapeutic strategy, treating tumor-bearing mice with anti-tumor mAb
activates complement enhancing the opsonization of tumor cells with iC3b. Blockade of
the membrane complement regulatory protein CD55, results in an increase in the
production of the chemotactic factor C5a and subsequent neutrophil infiltration in the
tumor, increasing the efficacy of anti-tumor mAb treatment combined with

β-glucan

administration in tumor-bearing mice (106). Amplification of C5a-mediated neutrophil
recruitment was also shown to be dependent on the presence of leukotriene B4 (107).
b) Lactosylceramide (LacCer)
In an attempt to explore the mechanisms of inflammation induced by the fungal pathogen
Pneumocystis, a causative agent of pneumonia in humans, Limper group conducted a series
of studies to investigate the role of β-glucan isolated from Pneumocystis fungal species
(PCBG) (108-112). In human DC, PCBG stimulated the production of IL-23, IL-6 and IL1β (108). Human DC treated with PCBG also induced CD4+ T cells to secrete IL-17 and
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IL-22, which are known to stimulate Th17 responses. In this study, Carmona et al. showed
that activation of human DCs by PCBG involved the Dectin-1 receptor leading to Syk
activation, Erk phosphorylation and the stimulation of the NF-kB canonical and noncanonical pathways. Interestingly, the secretion of IL-23 and the DNA binding of NF-kB
p65 subunit, following PCBG stimulation, also depended on the formation of
glycosphingolipid rich rafts (micro-domains) containing lactosylceramide in the DC
plasma membrane, implying that β-glucan might induce the mobilization and concentration
of lactosylceramide in the DC plasma membrane, leading to the initiation of the subsequent
signaling events. The formation of glycosphingolipids microdomains was also shown to be
important in alveolar epithelial cells (AECs) challenged with PCBG. Evans et al.,
demonstrated that glycosphingolipids microdomains are essential for the internalization of
fluorescent-labeled PCBG, the localization of protein kinase C (PKC) to AEC
microdomains (112), and the production of the macrophage inflammatory protein (MIP-2)
and TNF-α (111). Since AEC lack the expression of dectin-1 receptor, these studies
highlight the role of lactosylceramide as an alternate β-glucan receptor (108, 109, 111,
112). Lactosylceramide was also shown to be required for the secretion of the neutrophil
chemoattractant protein IL-8, mediated by a calcium-dependent MAPK signaling, in a
human airway epithelial cell line (1HAEo-) stimulated with PCBG (109).
Limper group, also showed that human DC stimulated with β-glucans, isolated from
Pneumocystis species or the yeast S. cerevisiae, upregulated the expression of the
costimulatory molecules CD40, CD80 and CD86, the lymph node homing chemokine
receptor CCR7, and the expression of Fas and the anti-apoptotic factor FLIP (110).
Interestingly, Fas-FasL interaction seems to be important for the induction of Th1
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responses mediated by DC treated with β-glucan. Carmona et al., showed that abrogation
of Fas-FasL by a FasL inhibitor impaired the production of IL-1β and TNF-α (but not IL12) by DC, and subsequently IFN- production by co-cultured T cells (110). More studies,
however, need to be conducted to further identify the mechanisms of glycosphingolipid
signaling following β-glucan challenge in DC.
c) Selected scavenger receptors (SRs)
Scavenger receptors (SR) were first identified on macrophages to mediate uptake and
degradation of acetylated low density lipoprotein (AcLDL) leading to the deposition of
cholesterol (113). This receptor recognized maleylated LDL, maleylated albumin, and the
sulfated polysaccharides fucoidin and dextran sulfate (113). Later studies identified
carboxymethy-β-1,3-glucan (CMG) and zymosan binding affinity to SRs. Vereschagin et
al. (114) showed that the uptake of AcLDL by rat macrophages decreased after co-injection
with CMG. Similarly, Dushkin et al demonstrated that SRs were induced after repeated
injections of CMG in rats, and that CMG competed with AcLDL for SRs (115). In addition,
the uptake of AcLDL by resident peritoneal macrophages in mice decreased by zymosan
(116). A biochemical study performed by Rice et al. identified SR as pattern recognition
receptors for (1,3)-β-glucans in human U937 monocytes (94). Further elucidating the
mechanisms of SR binding to yeast, Wang et al. demonstrated that SR-AI and SR-AII on
RAW264.7 macrophages mediate the binding to S. cerevisiae and C. albicans and that
transfection of CHO cells with SR-AI or SR-AII induces the internalization of S. cerevisiae
compared to non-transfected cells (117). Furthermore, a new scavenger receptor with a
collectin-collagen-like domain, called collectin placenta 1 (CL-P1), was identified on
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endothelial cells, but not monocyte-macrophage cells, that binds to S. cerevisiae (118).
Interestingly, the activation state of J774 macrophage cell line impacted the mechanism of
yeast recognition by SRs (119).
In macrophages pre-activated with theTLR9 ligand, CpG-ODN, the scavenger receptor
SR-A mediates the uptake of zymosan, but not C. albicans. In addition, the scavenger
receptor MARCO is involved in the uptake of zymosan and C. albicans in CpG-ODN
treated macrophages (119). However, in macrophages not treated with TLR9 ligand, the
uptake of zymosan seems to be mainly mediated by other β-glucan receptors.
d) Dectin-1
The anti-tumor effects of β-glucans through the activation of DCs have been only
highlighted after the discovery of dectin-1 receptor in DCs. Dectin-1, or DC-associated Ctype lectin, is a C-type lectin first described in the mouse DC line XS52 by Ariizumi et al.
(95) as a type II membrane-integrated polypeptide with a single carbohydrate recognition
domain (CRD) at the COOH-terminal end and with a cytoplasmic domain consisting of a
tyrosine-based activation motif (ITAM), or hemITAM in dectin-1 due to the presence of a
single tyrosine motif YXXXL (x is an amino acid) instead of the two motifs described in
other PRRs (95, 120). The generation of a novel dectin-1 mAb (2A11) allowed the
detection of dectin-1 on DC, macrophages, neutrophils and in a subset of T cells (121, 122).
Furthermore, immunohistochemical identification of dectin-1 showed its expression on
neutrophils, macrophages in the splenic red and white pulp, alveolar macrophages, Kupffer
cells, macrophages and DC in the lamina propria of the gut (123). Notably, the extracellular
C-type lectin-like fold of dectin-1 was independent on metal ions for zymosan binding,
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unlike classic Ca2+- dependent C-type lectins (120). Actin-dependent phagocytosis of
zymosan by RAW.2647 macrophages was also shown to be mediated by dectin-1
recognition (120). In an attempt to identify additional dectin-1 ligands, Palma et al. (124)
applied the neoglycolipid-based oligosaccharide microarray technology, to screen for
possible polysaccharide ligands for dectin-1. It was demonstrated, by this “designer”
microarray, that dectin-1 exclusively binds to glucose polymers with (1,3)-linkages.
Brown et al. initially identified the role of dectin-1 as a major β-glucan receptor on
macrophages (122). In this study, treating macrophages with specific dectin-1 mAb, but
not CR3 mAb (5C6), abrogated the recognition of unopsonized FITC-labeled zymosan
particles by thyoglycollate (Tg)-elicited peritoneal macrophages. In addition, soluble βglucan and particulate β-glucan inhibited the uptake of labeled zymosan particles by
macrophages and the uptake of non-opsonized zymosan particles was impaired in dectin1 knockout macrophages (125). Dectin-1-deficient macrophages also showed an impaired
respiratory burst in response to non-opsonized zymosan, which was restored when
stimulating macrophages with complement-opsonized zymosan (125).
Characterization of the human homologue of dectin-1 (Gene Bank accession number
AY009090) identified two major isoforms (A and B), and 6 minor isoforms (C-H) that
originate from alternative splicing (120, 126). Interestingly, human dectin-1 isoforms have
different affinities for β-glucan binding, with the two major splice variants (A and B) of
human dectin-1 being functional in β-glucan binding (126). Similar to murine dectin-1
human dectin-1 binds to unopsonized zymosan particles, S. cerevisiae and C. albicans in a
β-glucan-dependent manner (126). Human dectin-1 was also shown to be widely
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distributed in different cell types, including monocytes, monocyte-derived DC, DC derived
from peripheral blood or DC differentiated from CD34+ progenitors in the peripheral
blood, neutrophils and eosinophils (127, 128), monocyte/macrophage (U937) cell line,
HEK293T fibroblast cell line, B-cell (Daudi and Raji) and T-cell (CEM, Molt-4, Hut 78,
and Jurkat) lines (126). With human dectin-1 B isoform being significantly expressed on
immature DC and mature monocyte-derived macrophages (128).
In addition to its role as a pattern recognition receptor (PRR), human and murine dectin-1
was also shown to directly interact with T cells stimulating their effector functions (95,
122, 126, 128). A recombinant mouse dectin-1 with a soluble extracellular domain induced
T cell proliferation, and β-glucan was not able to inhibit the binding of T cells to NIH3T3
cells expressing dectin-1, suggesting the presence of a T cell binding site on dectin-1, apart
from the lectin-site (95, 120, 126). Moreover, HeLa cells transfected with human dectin1b cDNA induced the proliferation and IFN-gamma production of CD4+ and CD8+ Tlymphocytes (127). Human Dectin-1 in immature monocyte-derived DC also mediates the
uptake of apoptotic cells and CMV-infected human foreskin fibroblasts (HFF) and
subsequent cross-presentation of CMV peptides loaded on MHCI molecules to antigenspecific CD8+ T lymphocytes (129).
Elucidating the mechanisms of β-glucan activation from different sources has been a main
goal to understand the immune evasion strategies evolved in fungal pathogens, and the
immunomodulatory effects of β-glucan in cancer models (Table 1). Activation of DC by
β-glucan was also shown to be a potent strategy to induce tumor regression in tumorbearing animals (49, 130). It was reported by Li et al. and Qi et al. that orally administered
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particulate β-glucan WGP is effective in inducing tumor regression in mice bearing LLC
(Lewis Lung Carcinoma) or RAM-S-MUC1 lymphoma (49, 130). Interestingly, in orally
fed mice, WGP trafficked to the spleens and lymph nodes and activated DC in vivo. WGP
was also shown to enhance the ability of DC to capture tumor cells and induced the
expression of CD80, CD86 and MHC class II, and promote TH1 responses by stimulating

Table 1. The main cytokines produced and T cells activated upon bone marrowderived dendritic cells (BMDCs) stimulation with zymosan, curdlan and WGP.

the production of IL-6, IL-12 and TNF-α, depicted by the stimulation of a higher
percentage of IFN-gamma producing CD8+ T cells and the proliferation of antigen-specific
CD4+ and CD8+ T cell (49, 130).
The mechanisms of activation of β-glucan in tumor-bearing mice differ depending on the
type of physical properties and structure of the β-glucans. For example, WGP activation of
DC was shown to be dependent on dectin-1 receptor, whereas yeast-derived soluble βglucan binding to DC or macrophages was independent on dectin-1 (49). Goodridge et al.
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further demonstrated that despite the ability of dectin-1 to bind soluble and particulate βglucans, signaling events downstream dectin-1 are only triggered by particulate β-glucans
(48). This discrepancy in signaling was attributed to the ability of particulate-β-glucan to
trigger the formation of ‘phagocytic synapse’ that leads to the exclusion of the tyrosine
phosphatases CD45 and CD148 upon engagement of dectin-1 receptor on DC and
macrophages with particulate β-glucans on the microbe (48).
Signaling events downstream dectin-1 activation were initially reported in bone marrowderived macrophages and peritoneal macrophages (131). Underhill et al. reported that
dectin-1 signals through an ITAM-like, and activation of dectin-1 by zymosan leads to the
phosphorylation of spleen tyrosine kinase (Syk) dependent on the presence of Src family
kinases, and subsequently enhancing the production of reactive oxygen species (ROS).
Phagocytosis of zymosan was independent on Syk activation, or CD11b and FcRγ chain.
Interestingly, the response of macrophages to zymosan stimulation was heterogenous with
only a subpopulation activating Syk phosphorylation and ROS production. Rosas et al.
(132) demonstrated that macrophages irresponsive to β-glucan particles, such as curdlan,
can be reprogrammed by priming with GM-CSF to produce a cytokine profile similar to
BMDC. Syk activation was also enhanced by cytokines such as IFN-gamma and IL-4
(131). GM-CSF production in human-derived monocytic DC seems also to be enhanced
after zymosan treatment, increasing the levels of IL-23 secretion by DC (133). In bone
marrow-derived DC (BMDC) upon dectin-1 stimulation (Figure 2), Gross et al. (134)
reported the activation of the caspase recruitment domain protein 9 (CARD9) downstream
Syk. CARD9 functions as an adaptor protein that mediates the formation of Bcl10-Malt 1
complex activating NF-kB pathway. BMDC deficient in CARD9 or BCl10-Malt-1 showed
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impaired production of the cytokines TNF-α, IL-6, IL-12, IL-2 and IL-10 in response to
zymosan compared to wild-type BMDC. In contrast, Taylor et al. reported an impaired
production of IL-10 or IL-12 by dectin-1 knockout macrophages but not BMDC in
response to zymosan (125).
Dectin-1-Syk-CARD 9 signaling in response to curdlan stimulates the maturation of
BMDC through the upregulation of CD80, CD86 and CD40, and the increase in the
secretion of proinflammatory cytokines such as IL-2, IL-10, IL-6, tumor necrosis factor
(TNF), and IL-23 in preference to IL-12 (135, 136). DC stimulated with curdlan induces
the differentiation of IL-17 producing CD4+ T-cells in vitro, and promotes the
differentiation of TH17 and IFN-gamma producing CD4+ T cells in vivo (135) coupling
innate immunity to adaptive immunity. Similarly, C. albicans in the hyphae form
stimulates the differentiation of IL-17-producing CD4+ T cells, whereas the yeast form
promotes the differentiation of IFN-gamma producing CD4+ T cells (137). In agreement
with these findings, dectin-1 activation by the fungal pathogens, Histoplasma capsulatum,
Aspergillus and Rhizopus triggers the production of IL-23 by human DC stimulating TH17
responses (138).
A mechanism of negative regulation of Dectin-1-induced activation of DC seems to be
mediated by the peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligand
troglitazone (TGZ) through the manipulation of CARD9 signaling (139). TGZ inhibits the
expression of CARD9 impairing the localization of NF-kB to the nucleus (139). In
addition, PPAR-γ activation decreases antigen presentation in DC, impairs cytokine
production and DC-mediated T-cell proliferation. Hernanz-Falcon et al., demonstrated that
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attenuation of dectin-1 signaling can also be achieved by dectin-1 internalization through
phagocytosis (140).
The production of IL-2, IL-10, IL-12p70 and cyclooxygenase-2 (Cox-2) by zymosanstimulated DC and macrophages was also shown to be regulated by the protein NFAT
(141). NFAT activation is triggered by dectin-1 stimulation, and regulates the induction of
the early growth response (Egr) family transcription factors Egr2 and Egr3, whereas IL-6
and TNF-α production was not dependent on NFAT activation (141).
Stimulation of Dectin-1 in BMDC with β-glucans such as curdlan or zymosan, induces the
activation of mitogen activated protein kinases (MAPK) and NF-kB (134, 135, 142, 143).
For example, stimulation of BMDC with curdlan promotes the activation of p38, Erk1/2,
Jnk and NF-kB in a Syk-dependent or independent fashion (135, 139). Dectin-1 stimulation
on human DC by curdlan and C. albicans, induces the activation of the canonical NF-kB
pathway through p65 and c-Rel activation and non-canonical NF-kB pathway through the
activation of RelB (143). Dectin-1 activation also induces a Syk-independent Raf-1kinase
mediated pathway. Raf-1 activation converges with Syk-pathway at the NF-kB through the
inhibition of Syk-dependent RelB through the formation of RelB-p65 dimers, and promotes
p65 acetylation and c-Rel activation. The regulation of NF-kB downstream dectin-1
signaling couples innate to adaptive immune responses activating different cytokine
profiles that differentially regulates adaptive immune responses (143). Raf-1 activation
induces the expression of IL-12p70, a TH1 polarizing cytokine, and the production of IL1β, IL-6 and IL-23 that mediate TH17 differentiation.
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Various studies reported the cooperation or cross-talk between dectin-1 and other PRRs on
DC, macrophages and neutrophils. Cross-talk between TLR2 and dectin-1 pathways was
reported in DC and macrophages stimulated with zymosan (144, 145). In this model,
zymosan particles bind simultaneously to dectin-1 and TLR2/CD14. Dectin-1 activation
induces zymosan phagocytosis, the production of ROS, and along with TLR2, the
production of proinflammatory cytokines such as IL-12 and TNF-α through the activation
of NF-kB. Since zymosan does not consist entirely of β-glucan, the TLR2 ligand on
zymosan is yet to be identified. In contrast, Dillon et al., reported the induction of
regulatory DC by zymosan. In this study, zymozan activation of dectin-1 and TLR2 in DC
and macrophages stimulated the production of ERK-dependent IL-10 and biologicallyactive TGF-β, respectively (145). The production of IL-10 and TGF-β impaired the
production of IL-6, IL-12p70 and TNF-α, favoring the induction of CD4+ regulatory T
cells (Tregs). Interestingly, Osorio et al. reported the generation of T regulatory cells with
a hybrid phenotype, co-expressing Foxp3 and ROR-γt producing IL-17 upon coculture of
Foxp3+ Tregs with DC treated with Curdlan (146). However, treating D2SC/1 dendritic
cell line with WGP, not a stimulator of TLR signaling (48), was shown to upregulate the
expression of membrane glucocorticoid-induced tumor necrosis factor receptor ligand
(mGITRL) decreasing the suppressive activity of Tregs and promoting the proliferation of
CD4+ effector T cells (147). Discrepancies in these results with other groups might be due
to the use of different cell-lines, mice strains, types of glucans applied, and purify of
different glucan preparations (145).
Dectin-1 receptor was also shown to cooperate with the mannan receptor SIGNR1
(dendritic cell-specific ICAM-3 grabbing nonintegrin homolog related-1) in the
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nonopsonic internalization of zymosan in RAW264.7 macrophages (148). Kankkunen et
al. demonstrated that β-glucan induces the production and secretion of IL-1β through the
activation of NLRP3 inflammasome in macrophages (149). Interestingly, in a recent report,
Li et al. demonstrated that stimulation of neutrophils by C. albicans induce the activation
of dectin-1 which subsequently activates CR3 integrin

(Mac-1, CD11b/CD18) (150).

Binding of dectin-1 to C. albicans induces ITAM phosphorylation by Src kinases and
recruitment and phosphorylation of Syk, leading to the activation of the Vav/PLCγ
complex and Ca2+ activating CR3 that subsequently binds to the yeast. Activation of CR3
initiates a series of signaling events leading to the activation of ERK, PAK and Pyk2
through activation of Vav/PLCγ complex initiated by dectin-1 activation. Activation of
such targets stimulates cytoskeleton rearrangement required for phagocytosis and the
production of ROS in activated neutrophils (150).
Future studies will further delineate the signaling events downstream dectin-1 activation
by PAMPs, and its cooperation with other PRRs on signal transduction in immune cells.
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Figure 2. A schematic model summarizing the main signaling pathways in bone-marrow
derived dendritic cells (BMDCs) upon stimulation of dectin-1 with WGP, Zymosan and
Curdlan.
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II.

Myeloid-derived Suppressor Cells (MDSC)

1. MDSC origin
During differentiation hematopoietic stem cells (HSCs) diverge at a ‘decision-making
point’ to common lymphoid progenitors (CLPs) to generate NK cells, T cells or B cells or
common myeloid progenitors (CMPs) to generate monocytes, granulocytes, macrophages,
dendritic cells (DC), megakaryocytes and erythrocytes in the presence of appropriate
factors (151). Since MDSC are a heterogeneous population of monocytic or granulocytic
cells with a suppressive property, their origin and factors determining their fate, phenotype
and function in cancer is controversial and need to be further elucidated. A common
monocyte progenitor (cMoP) from monocyte-macrophage DC progenitor (MDP) that gives
rise to monocytes or monocyte-derived macrophages was recently identified (152). Under
inflammatory conditions, cMoP differentiate into monocytes which can further
differentiate into tissue-resident macrophages (152), consistent with the finding that
MDSC in the tumor microenvironment differentiate toward tumor-associated macrophages
(TAMs) via HIF-α induced by tumor hypoxic conditions (39). MDSC can be induced from
bone marrow (BM) precursors in the presence of the tumor-derived factors granulocytemacrophage colony stimulating factor (GM-CSF) and IL-6 (153). Inhibition of paired
immunoglobulin-like receptor-B (PIR-B) or C/EBPβ promotes MDSC differentiation to
macrophages, granulocytes and DC with no suppressive function, suggesting that the
suppressive function of MDSC induced by tumor factors is reversible (153, 154).
The origin and fate of Ly6Chigh and Ly6Clow monocytes are subject to further exploration,
especially that Ly6Chigh monocytes with suppressive properties identified as M-MDSC
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have been widely studied in inflammation and cancer. It is still controversial whether
Ly6Chigh monocytes differentiate to Ly6Clow monocytes or whether both monocyte subsets
arise from independent precursors (155-159). In EL4 mouse thymoma-bearing mice,
splenic Ly6Chigh (Gr1int CD11b+) M-MDSC transferred to tumor-bearing mice are able to
give rise to all CD11b+ subsets including Gr-1high granulocytes (160). Similarly, Youn et
al. recently demonstrated that M-MDSC (CD11b+Ly6Chigh) in tumor-bearing mice could
differentiate into granulocytic MDSC expressing CD11b+ Ly6G+ Ly6C- (40). This
differentiation was mediated by epigenetic silencing of the retinoblastoma gene in MMDSC mediated by histone deacytylase 2 (HDAC-2). These findings highlight M-MDSC
plasticity and its potential to give rise to PMN-MDSC. It is still debatable whether PMNMDSC consist solely of immature myeloid cells with suppressive function or whether
mature neutrophils can acquire suppressive properties in the tumor milieu. A study by
Fridlender et al identifies TGF-β as the inducer of suppressive neutrophils in the tumor
(N2), since blockade of TGF-β enhances the recruitment and activation of neutrophils with
anti-tumor functions (N1), suggesting that neutrophils can be polarized in tumor-bearing
animals or potentially in cancer patients toward a suppressive phenotype (161).
Transcriptomic analysis revealed differences between tumor-associated neutrophils
(TANs), splenic PMN-MDSC, and neutrophils from naïve mice (162). Compared to
neutrophils from naïve mice, TANs display lower expression of cell-cytotoxicity genes, a
higher expression of MHC II complex genes and inflammatory cytokines (e.g. TNF-α, IL1α/β), and upregulation of chemoattractants of T cells, B cells, neutrophils and
macrophages. Interestingly, neutrophils from naïve animals are more closely related to
splenic PMN-MDSC than to TANs.
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Unlike neutrophils from naïve mice, splenic PMN-MDSC are immune suppressive and
express higher levels of M-CFSR, CD244, arginase, MPO and ROS, with a lower
phagocytic activity (163). A recent study has reported that tumor-promoting neutrophils
are recruited to the tumors by tumor-derived oxysterols in a CXCR2-dependent manner,
promoting tumor growth and neoangiogenesis (164). Future studies will further unveil the
exact origin of MDSC and its relation to other myeloid subsets in cancer.
2. MDSC mechanisms of suppression
Tumor-infiltrating immune cells with a suppressive phenotype include regulatory T cells
(Tregs), γδ T cells (165, 166), suppressive TAMs, and MDSC. The detailed mechanisms
of MDSC suppression were recently described elsewhere (33, 38, 167). Herein, we briefly
highlight the main suppressive mechanisms employed by MDSC in cancer.
Although MDSC subsets share the ability to suppress T cell activation, their different
mechanisms of function, recruitment and expansion in tumor-bearing animals are being
constantly highlighted. In general, MDSC expansion is induced by tumor factors such as
GM-CSF (168), stem-cell factor (SCF-1)(169), prostanglandin E2 (PGE2) (170),
cyclooxigenase-2 (COX-2) (171), vascular endothelial growth factor (VEGF) (172),
macrophage colony-stimulating factor (M-CSF) and IL-6 (173). MDSC suppress T cell
activity mainly by modulating L-arginine metabolism through the upregulation of arginase1 (Arg1) and inducible nitric oxide synthase (iNOS) in M-MDSC, and Arg1 and reactive
oxygen species (ROS) upregulation in G-MSDC (38). Arg1 catalyzes the conversion of Larginine to L-ornithine, while iNOS mediates NO production from L-arginine, ultimately
leading to the production of urea (38). L-arginine starvation induces the loss of the CD3ζ
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chain (174), and inhibition of T cell-cycle progression by restraining the upregulation of
cyclin D3 and cyclin-dependent kinase 4 (cdk4) (175). In addition, NO induces Fasdependent apoptosis (176) and inhibits proteins downstream IL-2 receptor (177).
Moreover, reactions between NO and ROS, such as superoxide ions, produce peroxinitrite
that impact CD8+ T cell activity by inducing the nitration of CD8+ T-cell receptor (TCR)
restraining its recognition by the MHC peptide (167). MDSC also deprive T cell from
cystein, an essential amino acid required for T cell activation (46). T cells do not produce
cysteine and depends on APCs for cysteine supply after they uptake cystine. However,
MDSC limit cystine pool available for APCs depriving T cells from cysteine (46).
M-MDSC and PMN-MDSC suppressive activities are thought to also diverge in the
expression and phosphorylation of signal transducers and activators of transcription
(STATs). PMN-MDSC suppressive functions are thought to be mainly mediated by
STAT3 phosphorylation, while STAT1 seems to play a main role in M-MDSC suppressive
biology (167). Current studies show that STAT3 phosphorylation is a key event in
regulating PMN-MDSC suppressive activity and inhibition of differentiation through
various mechanisms. STAT3 phosphorylation enhances the production of ROS through the
activation of calcium-binding proteins S100A9 and S100A8 (178) which are involved in
the formation of NAPDH oxidase complex (Nox-2) (179). In addition, upregulation of
Nox-2 subunits, such as p47phox and gp91phox, are directly related to the enhanced
production of ROS by PMN-MDSC augmenting its suppressive activity (167). STAT3 not
only promotes the suppressive activity and expansion of MDSC, but also induces
tumorigenesis by mediating the production of myeloid-derived angiogenic factors such as
VEGF (180). STAT3 immunosuppressive functions of MDSC can also be mediated by
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Hsp72 from tumor-derived exosomes (181). On the other hand, M-MDSC suppressive
activities are mediated by factors that regulate Arg1 and iNOS production, such as STAT1.
STAT1 activation is mediated by IFN-γ and IL-1β and is thought to play an important role
in M-MDSC suppressive activity due to the fact that blocking IFN-γ or disrupting STAT1
partially reduced M-MDSC suppressive functions (31). However, a recent study
demonstrated that expression of IFN-γ and IL-4Rα is not required for T-cell suppression
by MDSC, since MDSC from IFN-γ-/-, IFN-γR-/- and IL-4Rα-/- tumor-bearing mice
suppress CD8+ and CD4+ T cells (182).
MDSC immunosuppression also extends to a vast network of immune cells including
Tregs, macrophages, and NK cells. MDSC induce the recruitment and expansion of Tregs
in tumor-bearing mice through the production of IL-10 and TGF-β (183), dependent on
CD40-CD40L interaction (45). IL-10 production by MDSC also decreases IL-12
production in macrophages enhancing Th2 responses in tumor-bearers (184).

However,

a controversial report demonstrated that TGF-β mediated generation of induced Tregs
(iTregs) (CD4+CD25+Foxp3+) and proliferation of natural Tregs (nTregs) is impaired by
PMN-MDSC (185). NK cell activity is also suppressed by MDSC. MDSC from the liver
and spleen of tumor-bearing mice inhibit NK cell cytotoxicity, NKG2D expression and
IFN-γ through membrane-bound TGF-β in tumor-bearers (44) or NKp30 receptor
expression on NK cells in patients with hepatocellular carcinoma (186). Interestingly, a
recent report has demonstrated that NK cells can be converted to MDSC in the presence of
GM-CSF (187). However, this finding has to be further confirmed since NK cells share a
common lymphoid progenitor with T and B cells but not myeloid cells (151).
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3. Therapeutic Targeting of MDSC
It is now being greatly highlighted that exploring immunosuppressive regulation by MDSC
in the tumor microenvironment will bring a new paradigm in our understanding of cancer
as well as for devising novel immunotherapeutic approaches. In recent years, many
approaches have been developed with the goal of abolishing their suppressive activity in
vivo as a therapeutic intervention in cancer. In the following, we discuss different
therapeutic strategies applied in the modulation of MDSC in tumor-bearing mice and
cancer patients including inhibition of MDSC suppressive function, expansion,
recruitment, and induction of MDSC differentiation (Figure 3).
A. Inhibition of MDSC suppressive function
1- Inhibitor of Reactive Nitrogen Species (RNS) (AT38)

Murine
RNS produced by MDSC and tumor cells such as peroxynitrite anion induces the nitration
of the chemokine CCL2 preventing the migration of CTLs to the tumor core. Targeting of
RNS with AT38 ([3-(aminocarbonyl) furoxan-4-yl] methyl salicylate) in mice bearing
subcutaneous colon carcinoma expressing GM-CSF (C26GM), or thymoma expressing
OVA (EG7-OVA), or spontaneous prostate cancer (TRAMP mice), downregulated Arg1,
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Figure 3. The main therapeutic compounds targeting MDSC suppression,
expansion, recruitment and differentiation in cancer.
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iNOS and peroxinitrite in MDSC, enhanced survival and improved the efficacy of adoptive
transferred tumor-specific CTLs (188).
2- Nitroaspirin
Murine
NO-donating aspirin (NO aspirin) consists of an aspirin molecule covalently linked to a
NO donor group. The effects of different NO-donating aspirins (NCX4060, NCX4016) on
MDSC suppressive activity in cancer were studied by De Santo et al (189). In BALB/c
mice inoculated with a colon adenocarcinoma expressing GM-CSF (C26-GM), treatment
with NCX4060 or NCX4016 restored T lymphocyte proliferation in MLR reactions or T
cells induced with anti-CD3 and anti-CD28 in the presence of MDSC, increased CTL
activity and reduced MDSC Arg1 and NOS activity, in vitro and in vivo. Despite these
effects on MDSC suppressive function, treatment of tumor-bearing mice with NCX4016
orally did not significantly decrease tumor burden or prolonged survival except only when
coupled to a recombinant DNA vaccine in two vaccination models:
a) Vaccination of BALB/c mice with a plasmid encoding the full-length env gene
(pcDNA3-env), challenged with colon carcinoma CT26 (gp70 positive) subcutaneously,
and orally treated with NXC4016.
b) Immunization of BALB/c mice with a plasmid DNA encoding p186 (extracellular and
transmembrane portion of HER-2/neu) prior to challenging with a mammary carcinoma
cell line N2C.

3- Phosphodiesterase-5 Inhibitors (Sildenafil)
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Murine
Inhibition of cGMP phosphodiesterase gene family 5 (PDE-5) induces apoptosis of colon
cancer cells through the induction of cGMP protein kinase (PKG) in colon tumor cells
(190) or apoptosis of B-cell chronic lymphocytic leukemia (B-CLL) cells in a caspasedependent manner (191). Treatment of mice with Sildenafil, a PDE-5 inhibitor, delayed
the progression of tumors in mice inoculated with different tumor cell lines including colon
carcinoma (CT26WT), colon carcinoma expressing GM-CSF (C26GM), mammary
adenocarcinoma (TS/A), MCA203 fibrosarcoma (192), and a mouse transgenic melanoma
model (193). Interestingly, delayed tumor progression was associated with the modulation
of T cell immune suppression by MDSC towards a less suppressive phenotype. Treatment
of tumor-bearing mice with Sildenafil given in the drinking water, decreased the expression
of IL-4Rα, Arg1, NOS2 in tumor infiltrating CD11b+ cells, increased the efficacy of
adoptive T cell transfer therapy (ACT), induced the infiltration of tumor infiltrating
lymphocytes (TILs) including CD8+ and CD4+ T lymphocytes (192, 193), partially restored
the expression of CD3ζ chain in CD8+ and CD4+ T lymphocytes infiltrating skin
melanomas and metastatic lymph nodes, increased IL-2 levels and decreased the levels of
IL-1β, VEGF, GM-CSF, IL-6, S100A9, and the chemokines CCL2 (MCP-1) and CCL3
(MIP-1α) in metastatic lymph nodes in melanoma-bearing mice (193). The exact
mechanism of linking the accumulation of cGMP in MDSC with L-arginine metabolism is
not fully elucidated. Although Sildenafil delayed tumor growth in different mice models,
tumor eradication was not achieved suggesting the importance of the combined targeting
of a network of immune cells with a suppressive phenotype in the tumor
microenvironment.
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Human
PBMCs from patients with multiple myeloma (MM) or head and neck squamous cell
carcinoma (NSCLC) stimulated in vitro with plate-coated anti-CD3/anti-CD28 Abs in the
presence or absence of Sildenafil or Arg1 inhibitor (NorNOHA) or NOS2 inhibitor ( LNMMA) restored the proliferation of CD3 cells. Interestingly, Sildenafil only restored the
proliferation of CD8+ T cells in PBMCs from NSCLC cancer patients. CD4+ T cell
proliferation in PBMCs from MM patients was still lower than PBMCs from healthy
donors (192). More studies need to be performed to demonstrate the significance of these
findings in humans, its toxicity, and its efficacy in the clearance of primary or metastatic
tumors.
4- Triterpenoids (CDDO-Me)
Murine
Treatment of mice-bearing colon carcinoma (MC38), Lewis lung carcinoma (LLC) or EL4 thymoma with a synthetic triterpenoid, CDDO-Me, abrogated MDSC suppressive
function through the downregulation of ROS and inhibition of STAT3, and inhibited tumor
growth. In addition, CDDO-Me enhanced the efficacy of survivin vaccine in vivo.
However, CDDO-Me treatment did not affect Arg1 and NO production or the frequency
of MDSC in the spleens of tumor-bearing mice (194).
Human
Treatment of patients with locally advanced (stage II-III) or metastatic (stage IV)
pancreatic cancer with CDDO-Me and gemcitabine in a Phase I clinical trial had no effects
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in the frequencies of MDSC in the peripheral blood with an increased response of T cells
from treated patients to tetanus toxoid and phytohemagglutinin. However, the effect of
CDDO-Me treatment was not assessed in the absence of gemcitabine (194).
5- Very small size proteoliposomes (VSSP)
Murine
VSSP is a nanoparticulated adjuvant that promotes DC maturation and enhances CD8+ T
cell effector function. Treatment of tumor-bearing mice with VSSP increases the
accumulation of MDSC in the spleen. However, MDSC from the spleens of VSSP-treated
mice are significantly less suppressive than non-treated mice, correlating with enhanced
CTL activity in mice treated with VSSP. In addition, VSSP treatment induces the
differentiation of MDSC into mature antigen-presenting cells (APC) (195). More studies
need to be performed to evaluate VSSP efficacy in the clinic.
6- Inhibition of exosome formation (Amiloride)
Murine
Amiloride inhibits exosome formation. It has been reported that membrane associated
Hsp72 from tumor-derived exosomes (TDEs) induce MDSC suppressive activity by
inducing the STAT3 phosphorylation in a TLR2/MyD88-dependent manner through
autocrine IL-6. Treatment of mice-bearing CT26, TS/A, or EL4 tumors with exosome
inhibitors such as amiloride, enhanced anti-tumor immune responses when combined with
cyclophosphamide(181). However, treatment of mice with exosome inhibitors alone did
not reduce tumor growth.
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Human
Treatment of patients with colorectal metastatic carcinoma with amiloride for 3 weeks
abrogated the suppressive activity of MDSC from peripheral blood ex vivo, and decreased
the ability of autologous serum to induce STAT3 phosphorylation in MDSC (181).
B. Inhibition of MDSC expansion
1- Gemcitabine and 5-Fluorouracil
Murine
Pyrimidine analogues, such as Gemcitabine (Gem) and 5-Fluorouracil (5-FU), have been
currently used in the clinic to induce tumor cell death and hamper tumor growth. Their
cytotoxic effects on MDSC in tumor-bearers have currently been described.
Administration of Gem and/or 5-FU selectively induced apoptosis of Gr1+CD11b+ MDSC
in the spleens and tumors of tumor-bearing mice, with no significant decrease in the levels
of CD4+, CD8+, B cells, NK cells or macrophages and enhanced IFN-γ production by
tumor-specific CD8+ T cells and NK cells (196-199). The anti-tumor effects of Gem were
enhanced when combined with other therapeutic protocols including chemotherapeutic
drugs, such as cyclophosphamide (200) and rozigliazone, (201) that target Tregs and
PPARγ respectively, or in combination with adenoviral based immunotherapy (202) or
IFN-β treatment (196). Despite promising effects in anti-tumor immunity, the ambivalent
effects of chemotherapeutic drugs, including Gem and 5-FU, is yet to be further explored.
Gem and 5-FU triggered the production of IL-1β in MDSC following the activation of the
inflammasome (NOD-like receptor family, pyrin domain containing-3 protein (Nlrp3)dependent caspase-1 activation complex) in a cathepsin-B dependent manner. Secreted IL39

1β then stimulated the production of IL-17 by CD4+ T cells inducing the expression of
angiogenic factors such as Eng and Pecam1 counteracting anti-tumor immunity (203).

2- Cyclooxygenase (COX-2) and Prostaglandin E2 (PGE2) inhibitors
Murine
COX-2 and PGE2 are produced by different human and murine cancer cells including LLC,
renal carcinoma, colon carcinoma MCA-38 and head and neck tumors (171). Targeting
COX-2 and PGE2 with inhibitors, such as indomethacin (204), celecoxib (205) , meloxicam
(206) and acetylsalicylic acid (ASA) (207), augmented tumor growth in different cancer
models. COX-2 inhibitors reduced systemic levels of PGE2, modulating MDSC
suppressive function, recruitment and induction. COX-2 inhibitors inhibited Arg1
expression in MDSC induced by tumor released factors such as COX-2 and PGE2, reduced
ROS and NO levels, enhanced T cells anti-tumor responses and improved the efficacy of
DC-based immunotherapy in tumor-bearing mice (171, 208).
ASA also regulated the recruitment of MDSC to the tumors by decreasing the levels of
MDSC-attracting chemokine CCL2 and increasing the expression of CXCL10 and CTL
infiltration in glioma (207). COX-2 is a PGE2 –forming enzyme that can also be activated
through PGE2 receptor EP2 in MDSC by PGE2 (170, 209). Induction of EP2 in MDSC by
PGE2 hampered their differentiation to mature APCs from the bone marrow (209), and
induced the generation of MDSC from monocytes in vitro by blocking monocyte
differentiation to mature CD1a+ DC and enhancing the expression of indoleamine 2,3dioxygenase (IDO), IL-4Rα, NOS2 and IL-10 (210).
Human
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CD14+ monocytes acquire MDSC phenotype through coculture with human melanoma
cells through a COX-2-dependent mechanism (211). In patients with advanced melanoma,
inhibition of PGE2, COX-2, STAT3 and superoxide in MDSC restored T-cell proliferation
in culture.
3- Sunitinib
Murine
Sunitinib, a tyrosine kinase inhibitor, targets a wide range of kinases including, plateletderived growth factor receptor (PDGFR), vascular endothelial growth factor receptors
(VEGFR1-VEGFR3), SCF, m-CSF and FMS-like tyrosine kinase 3 (FLT3) (212-214).
Sunitib is currently approved by the Food and Drug Administration (FDA) for the treatment
of patients with gastrointestinal stromal tumors (GIST) that failed to respond to Imatinib
(212, 215) and as a first-line treatment of patients with metastatic RCC (216, 217). In
addition to its angiogenic effects and targeting of tumor cells, sunitinib immune modulation
of suppressor cells, such as MDSC and Tregs, has been recently described (218-220).
Sunitib treatment decreased the percentages of MDSC and Tregs in the spleen of tumorbearers, reduced the expression of pro-tumorigenic factors in tumor infiltrating
lymphocytes (TILs) such as IL-10, TGF-β, Foxp3, CTLA-4 and PDL-1, skewing
suppressed T lymphocytes towards an anti-tumor Th1 phenotype, represented by the
increased levels of IFN-γ and CTL responses (218). Sunitib combined with IL-12 and 41BB activation prolonged survival of mice bearing MCA26 colon tumor, and increased the
anti-tumor efficacy of OVA-loaded DC vaccines in mice bearing subcutaneous B16
melanoma expressing OVA (218, 221). However, sunitinib modulation of tumor MDSC
seems to be compromised in tumors expressing high levels of GM-CSF, such as 4T1 or
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human RCC cells (222, 223). GM-CSF in the tumor microenvironment reprograms MDSC
to act independently on STAT3 through the induction of STAT5 phosphorylation,
bypassing the inhibition of STAT3 phosphorylation induced by sunitinib (219, 222, 223).
Another mechanism of tumor evasion from sunitinib treatment is the increased production
of the chemokine stromal cell-derived factor-1 (SDF-1; CXCL12) in the tumor
microenvironment following p53 activation induced by sunitinib, leading to increased
levels of MDSC in RCC xenografts (224).

Human
The clinical outcome of sunitinib treatment in patients with metastatic RCC is limited to
its ability to modulate immune suppression in the tumor rather than in the periphery (222,
223). Despite the encouraging findings that sunitinib treatment decreases the levels of
MDSC, Tregs and IFN-γ producing T lymphocytes in PBMCs of RCC patients (225, 226),
its effects on intratumoral MDSC and proangiogenic factors such as MMP-9, MMP-8 and
IL-8 in tumor explants were minimal (222, 223).
4- Blockade of stem cell factor (SCF; ckit ligand)
Murine
SCF is expressed by tumor cells, with a higher expression in large tumors. SCF production
in the tumor microenvironment enhances the accumulation of MDSC in the tumor. SCF
siRNA knockdown in tumor cells, and blocking SCFR-SCF binding with anti-ckit reduces
MSDC expansion and infiltration in the BM and tumor, reduced angiogenesis, enhanced T
cell proliferative responses and decreased Treg development in mice bearing MCA26 colon
carcinoma (169).
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5- Amino-biphosphonate (Zoledronate, Pamidronate)
Murine
Amino-bisphosphonates is a MMP-9 (metalloproteinase-9) inhibitor. The production of
MMP-9 by tumor and stromal cells is directly correlated with VEGF production in the
tumor microenvironment. Targeting MMP-9 by amino-biphosphate in mice with
spontaneous mammary carcinoma reduced the levels of pro-MMP-9 and VEGF in the
serum, tumor-enhanced BM hematopoiesis and improved anti-tumor responses induced by
DNA vaccination (227).
6- Doxorubicin-cyclophosphamide chemotherapy
Human
MDSC (Lin-

/low

CD33+CD11b+ HLA-DR-) percentages and absolute numbers in the

peripheral blood of breast cancer patients directly correlate with the stage of the disease;
patients in stage IV with extensive metastatic tumor having the highest numbers of
circulating MDSC and lowest T cell responses. Doxorubicin and cyclophosphamide are
common chemotherapeutic drugs included for the treatment of breast cancer. Interestingly,
patients treated with doxorubicin-cyclophosphamide displayed increased percentages of
MDSC in the peripheral blood but not when followed with paclitaxel treatment, suggesting
that treatment with doxorubicin-cyclophosphamide alone may not be favorable in the
development of anti-tumor immune responses in patients with breast cancer (228).

C. Inhibition of MDSC recruitment
1- Vemurafenib
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Human
Vemurafenib is a specific inhibitor of BRAFV600E (229), a mutation that causes constitutive
activation of the MAP Kinase pathway, a common mutation in melanoma patients (230).
Treatment of advanced melanoma patients with Vemurafenib decreased the frequencies of
M-MDSC (CD14+ HLA-DR-/low) and PMN-MDSC (CD66b+Arginase1+CD16-/low) in
PBMCs (229). The clinical course melanoma was correlated with an increase in the
percentage or M-MDSC and PMN-MDSC, with patients responding more to treatment
having lower percentages of M-MDSC, while PMN-MDSC percentages varied among
patients. Vemurafenib treatment is thought to modulate the tumor microenvironment
impacting MDSC induction since culturing PBMCs from healthy donors in a conditioned
media from a primary melanoma cell line in the presence of Vemurafenib failed to induce
CD14+HLA-DR-/low M-MDSC compared to cultures with no Vemurafenib (229). However,
it was not shown in this study whether Vemurafenib had direct effects on MDSC
suppressive functions.
2- Anti-G-CSF (granulocyte- colony stimulating factor) and anti-Bv8 antibodies
Murine
Bv8 (prokineticin-2) is upregulated in MDSC upon G-CSF receptor activation by G-CSF
(231). In tumor-bearing mice Bv8 induced angiogenesis, MDSC mobilization from the BM
to the tumor or distant sites establishing a pro-metastatic niche for the colonization of
metastatic tumor cells (231, 232). Overall, targeting the G-CSF-Bv8 axis in tumor-bearing
animals with specific antibodies decreased MDSC infiltration in the tumor, PMN-MDSC
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recruitment to the lungs of tumor-bearing mice, and decreased angiogenesis, tumor growth
and metastasis.
3- Anti-CSF-1 receptor (CSF1R) (GW2580)
Murine
GW2580 is a kinase inhibitor of CSF1R (233). Targeting CSF1R with GW2580 in LLCbearing mice decreased M-MDSC infiltration in the tumor with no effect on PMN-MDSC
recruitment, decreased the expression of Arg1 and MMP-9 in the tumors, and angiogenesis.
Interestingly, treatment of CSF-1 only impaired tumor growth when combined with
VEGFR-2 (vascular endothelial growth factor-2 receptor) (234).
4- Anti-CCL2 antibody
Murine
Inflammatory monocytes expressing Gr-1 and CCR2 (CCL2 chemokine receptor), in
response to CCL2 produced by tumor cells and stroma are preferentially recruited to
pulmonary metastases but not to primary tumor. Ablation of CCL2-CCR2 signaling with
anti-CCL2 antibody promoted tumor survival and decreased tumor metastasis by blocking
the recruitment of inflammatory monocytes to the lungs. Induction of tumor metastasis in
the lungs by inflammatory monocytes was dependent on the expression of VEGFA, since
inhibition of VEGFA expression in inflammatory monocytes abrogated the index of
metastases in the lungs (235).
5- CXCR2 and CXCR4 antagonists
Murine
Tumors with Tgfbr2 deletion induced the recruitment of MDSC through the production of
CXCL5 and SDF-1, that chemoattractted MDSC expressing CXCR2 and CXCR4. In mice
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inoculated with 4T1 mammary carcinoma, blockade of CXCR2 and CXCR4 significantly
decreased lung metastasis with no substantial difference in the growth of the primary
tumors (236).
D. Induction of MDSC differentiation
1- Vitamin D3
Human
Differentiation of suppressive CD34+ myeloid progenitors to DC by the differentiationinducing hormone 1α, 25-hydroxyvitamin D3, has been reported in mice bearing Lewis
Lung Carcinoma (LLC) and patients with NSCLC (237, 238). In a study conducted by
Kulbersh et al (238), 17 NSCLC patients were either treated (11 patients) or untreated (6
patients) with 1α, 25-hydroxyvitamin D3 for 3 weeks prior to surgery. Analysis of CD34+
and dendritic cells by immunohistochemistry in the NSCLC tissues revealed reduced
infiltration of intratumoral CD34+ cells and immature DC-SIGN+ dendritic cells and
increased numbers of intratumoral DC-LAMP+ mature DC.

To assess the clinical

significance of such findings, a clinical trial was conducted in 32 newly diagnosed patients
with NSCLC, with 16 patients left untreated or and the other 16 treated with 1α, 25hydroxyvitamin D3 for 3 weeks prior to surgical removal of the tumor (239).
Immunohistochemical analysis of the tumor revealed a significant increase in the levels of
intratumoral CD4+, CD8+ T lymphocytes and cells expressing the activation markers CD69
in patients treated with 1α, 25-hydroxyvitamin D3. To assess the significance of these
findings NSCLC patients were monitored for tumor recurrence after surgery, with median
recurrence being 181 days in the untreated group compared to 620 days in the treated group,
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emphasizing the importance of combining immune therapy by targeting suppressive cells
to surgical or chemotherapy procedures in the treatment of cancer. In another study to
determine the effects of 1α, 25-hydroxyvitamin D3 in the cytokine profiles in the plasma
and tumor tissue of NSCLC patients, it was reported that 1α, 25-hydroxyvitamin D3
differently modulates the cytokine milieu in the plasma compared to tumor tissue,
increasing the levels of IL-6, IL-10, IL-2, IFN-γ, TNF-α in the tumor tissue, and increased
levels of IL-8, VEGF, IL-1α and IL-1β in the plasma but not tumors of treated patients
compared to the levels in untreated patients (240). Although some studies have assessed
the effects of 1α, 25-hydroxyvitamin D3 on the cytokine profile of human monocytes and
macrophages in vitro (241), more studies need to be performed to link the effects of
different cytokine milieu in the tumor and plasma of cancer patients in differentiation of
immunosuppressive cells to mature DC.
In a recent report, fibrocytes expressing CD45+CD34+HLA-DR+ with a suppressive
phenotype were found to expand in patients with metastatic pediatric sarcomas,
demonstrating both features of neutrophilic and monocytic cells, suppressed anti-CD3
induced T cell proliferation through IDO, and its expansion correlated with an increased
Th2 phenotype in patients (242). Since 1α, 25-hydroxyvitamin D3 is believed to skew
CD34+ differentiation to mature DC, their effect in other types of cancers on suppressive
CD34+ cells is still to be elucidated.
2- Taxanes (Docetaxel and Paclitaxel)
Docetaxel and Paclitaxel are semi-synthetic taxanes with anti-tumor properties. These
drugs target tubulin in rapidly dividing cells, stabilizing microtubules during cell division
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leading to cell arrest and cell death. It has been reported in several studies that these taxanes
modulate immune responses in cancer patients and tumor-bearing mice (243, 244). Herein,
we summarize the main effects of Docetaxel and Paclitaxel on MDSC in murine tumor
models and cancer patients.
Murine
In a murine squamous cell carcinoma model, SCC VII/SF, docetaxel in conjunction with
vitamin D3 increased the numbers of intratumoral active T cells compared to vitamin D3
alone. However, docetaxel had no effect on the levels of CD34+ cells in the spleens and
lymph nodes, and no difference in tumor weight was found between untreated mice or mice
treated with vitamin D3 and/or docetaxel. It is important to note that the efficacy of vitamin
D3 treatment in clinical trials on the recurrence of NSCLC in patients was assessed pos
surgery (240), suggesting that additional procedures are required along with immune
therapy in the treatment of cancer.
In a mammary carcinoma model, 4T1-Neu, intraperitoneal treatment of tumor-bearing
mice significantly decreased tumor growth through the modulation of MDSC (245).
Docetaxel treatment decreased the percentage of splenic MDSC, decreased its suppressive
activity, increased T cells CTL activity, upregulated the expression of CCR7 (M1 marker),
MHC II, CD11c, CD86 in MDSC, and preferentially induced cell death of Mannose
Receptor (MR+; M2 marker) MDSC. Incubation of MDSC for 6 hours decreased STAT3
phosphorylation, suggesting that docetaxel directly modulates MDSC signaling. Consistent
with these findings, treatment of B16-melanoma-bearing mice with docetaxel following
total body irradiation (TBI), improved T cell transfer and dendritic cell therapy, improving
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CTL function in vaccinated mice, by targeting highly suppressive MDSC and blocking
their rapid reconstitution following TBI (246). However, the mechanisms of docetaxel
effects on MDSC differentiation and the presence of possible receptors have not been
identified.
Combination of ultra low-doses of Paclitaxel with a peptide vaccine derived from the
melanoma antigen Tyrosine related protein 2 (TRP2) enhanced vaccine efficiency in
healthy mice. The vaccine efficiency was associated with an increase in the levels of TRP2 specific T cells in the spleen, and correlated with decreased levels of Tregs and immature
myeloid cells, increased levels of effector CD8+ and CD4+ T lymphocytes in the bone
marrow and spleen, IFNγ-producing NK cells in the bone marrow and NKT cells in the
lymph nodes (247). Stimulation of MDSC in vitro with Paclitaxel in ultra-low doses
induced the expression of CD11c, CD86 and CD40 in a TLR4-independent manner (248),
suggesting that the decrease in the levels of MDSC in Paclitaxel-treated mice was due to
its differentiation to DC, however the levels of DC in tumor-bearing mice treated with
Paclitaxel was not speculated.
Human
The levels of circulating MDSC was assessed in a clinical trial involving forty-one women
diagnosed with HER-2 neu negative breast cancer in stages II-IIIa and received three
chemotherapeutic drugs: doxorubicin-cyclophosphamide followed by docetaxel every 3
weeks followed by NOV-002, a disodium glutathione disulfide (249). It was found that
patients who achieved pathologic complete response (pCR) (defined as no metastatic tumor
in the axillary lymph nodes, no invasive tumor in the breast or and invasive tumor ≤ 10mm
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in dimension) had lower levels of circulating MDSC (Lin-HLA-DR-CD11b+CD33+) in the
blood compared to patients who did not achieve pCR. In this study 15 out of 39 patients
achieved a pCR. Suggesting that MDSC targeting may increase the efficacy of
chemotherapy regimens currently used in the clinic.
3- All-trans-Retinoic s (ATRA)
Murine
Retinoic acid was previously shown to induce granulocytic differentiation of cells from
patients with acute promyelocytic leukemia in vitro (250). In mice bearing subcutaneous
C3 fibrosarcoma or DA3-HA mammary adenocarcinoma, treatment with subcutaneously
implanted ATRA pellets induced the differentiation of adoptively transferred MDSC to DC
(CD11c+ IAb+), macrophages (F4/80+) and granulocytes (Gr1+CD11b-), and improved
CD4+ T cell responses (251). Although treatment of tumor-bearing mice with ATRA
decreased the percentages of MDSC (Gr1+CD11b+) in the spleens and bone marrow of
tumor-bearing mice, it did not decrease tumor growth except only when combined with a
DC cell vaccine transduced with Ad-p53 (251). ATRA-induced differentiation of MDSC
from tumor-bearing mice and patients with renal carcinoma was shown to be through the
activation of glutathione synthase (GSS) and accumulation of glutathione (GSH) leading
to a neutralization of reactive oxygen species (ROS) in an ERK1/2-dependent mechanism
(252). In addition, ATRA enhanced the immunogenicity, and differentiation of MDSC
loaded with NKT cell ligand α-GalCer in a mechanism dependent on GSH activation in
MDSC and IFN-γ production by NKT cells (253).
Human
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ATRA induction of MDSC differentiation in murine models was extended to clinical trials
in patients with metastatic renal cell carcinoma (RCC) and small cell lung cancer (SCLC)
(254, 255). In RCC patients treated with ATRA prior to IL-2 treatment had reduced
numbers of MDSC, a higher myeloid/lymphoid dendritic cell ratio, and decreased the
suppressive activity of mononuclear cells (254). Interestingly, IL-2 treatment abrogated
ATRA effect. In vitro culture of MDSC from patients with metastatic RCC with ATRA
induced its differentiation to functional APCs, and abrogated its immune suppression
(256). Similarly, in patients with SCLC, ATRA treatment increased DC vaccine efficacy
decreasing MDSC levels in the peripheral blood and improving antigen-specific CD8+ T
cell responses (255).
4- TLR9 activation by CpG
Murine
Activation of TLR9 receptor in MDSC by CpG induced MDSC maturation and
differentiation, and abrogated MDSC suppressive function, especially PMN-MDSC, in
mice-bearing subcutaneous C26 tumors and in CEA424-Tag mice autochthonous gastric
tumors. MDSC differentiation and inhibition of suppressive function were promoted by
IFN-α produced by plasmacytoid DC (pDC) in vitro. However, the effect of IFN-α on
MDSC differentiation and function needs to be further elucidated (257).
5- Curcumin
Murine
In a human gastric cancer xenograft model and a mouse colon cancer allograft model,
treatment with curcumin in the diet or intraperitoneally decreased the percentage of MDSC
in the tumor, spleen and blood. PMN-MDSC percentage was decreased upon curcumin
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treatment, while M-MDSC differentiated to an M1-like phenotype with an increased
expression in CXCR7. Curcumin treatment of MDSC cocultured with cancer cells or
myofibroblast-conditioned medium in the presence of IL-1β inhibited p-Stat3 and IL-6
production by MDSC. However, it was not determined in this study whether curcumin
impacted MDSC suppressive function (258).
6- Whole-glucan particles (WGP)
Murine
Treatment of M-MDSC from LLC-bearing mice in vitro with WGP induced a population
of cells expressing CD11c+ F4/80+ Ly6Clow. M-MDSC suppressive function was also
decreased upon incubation with WGP. Oral treatment of LLC-bearing mice with WGP
significantly reduced the percentage of Gr-1+ CD11b+ cells and Tregs, and increased the
percentage of macrophages, DC and effector CD8+ T cells in vivo, with a significant
decrease in tumor burden (50). The effects of WGP on M-MDSC were dependent on Syk
and NF-κB p65 signaling.
The main therapeutic approaches applied up to date in the clinic to target MDSC in
cancer patients are summarized in Table 2.
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Table 2. Therapeutic targeting of MDSC in human cancer
Therapeutic drugs

Effect on MDSC

Overall Results

Inhibit MDSC
suppression

Restore T cell proliferation

Inhibit MDSC
suppression

Inhibitor of exosome
formation
(Amiloride)

Inhibit MDSC
suppression

-No effect on MDSC
frequency in peripheral
blood
- Induces T
cell proliferation in vitro
Decrease pStat3 in MDSC

COX-2 and PGE-2
inhibitors
(Celecoxib)

Inhibit MDSC
induction,
expansion and
suppression
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Phosphodiesterase-5
inhibitor
(Sildenafil)
Triterpenoid (CDDOMe) + Gemcitabine

Restores CD3 proliferation

Tissue/ type of
cancer
PBMCs; MM and
NSCLC
PBMCs; Stage IIIV pancreatic
cancer
PBMCs; colorectal
metastatic
carcinoma

Method
Sildenafil added in
vitro to PBMCs
cultures
Phase I trial
T cell activation
assessed ex vivo

Phase I trial
-MDSC suppressive
function assessed ex
vivo
- Serum from treated
patients have
decreased ability to
induce pStat3 in
MDSC
PBMCs; melanoma COX-2 and PGE-2
inhibitors added in
vitro to CD14+ and T
cell cocultures

Ref.
(192)

(194)

(181)

(211)

Dexorubicincyclophosphamide

Vemurafenib (BRAF
V600E inhibitor)
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Vitamin D3 (1α,25hydroxyvitamin D3)

Killing tumor cells
and Treg
modulation

-Increase MDSC
percentages in peripheral
blood; MDSC retained
suppressive activity
-Patients treated with after
with paclitaxel have less
increase in MDSC
percentages
Inhibit MAP kinase -Decreases frequency of Mpathway in tumor
MDSC (CD14+HLAcells
DRlow) and PMN-MDSC
(CD66b+Arginase1+CD16/low
) in PBMCs
Differentiation of
-Increases the numbers of
suppressive CD34+ TILs and cells expressing
myeloid progenitors CD69
to DC
-Delays tumor recurrence
pos surgery
-Increases the levels of IL6, IL-10, IL-2, IFN-γ, TNFα in the tumor
-Increases levels of IL-8,
VEGF, IL-1α and IL-1β in
the plasma

PBMCs; StageI/II,
stage III and stage
IV breast cancer

Percentages of MDSC
and suppressive
assays assessed ex
vivo after each cycle
of chemotherapy

PBMCs; Advanced
melanoma

Percentages of MDSC (229)
and suppressive
assays assessed ex
vivo in patients treated
with Vemurafenib
Immunohistochemical (237-241)
analysis of the tumor
of patients treated 3
weeks prior surgery

Tumor tissue;
NSCLC

(228)

doxorubicincyclophosphamide +
docetaxel every 3
weeks followed by
NOV-002, a disodium
glutathione disulfide
ATRA
(Vesanoid)+IL2

-Decrease levels of
circulating MDSC (LinHLA-DR-CD11b+CD33+)

Prior to IL-2
treatment ATRA
Induces MDSC
differentiation to
functional APC and
decreases MDSC
suppressive activity

Inhibitioon of
MDSC expansion

PBMCs; HER-2
neu negative breast
cancer in stages IIIIIa

Percentages of MDSC
in PBMCs assessed
after treatment

(243, 244)

-Reduce numbers of MDSC PBMCs; metastatic
-Increase
renal cell
myeloid/lymphoid dendritic carcinoma, SCLC
cell ratio
- No direct effect on tumor
growth
- Increased efficacy of DC
vaccine
-IL-2 treatment abrogated
ATRA effect

Clinical trial

(254, 255)

- Decreases the levels of
MDSC, Tregs and IFN-γ
producing T lymphocytes
in PBMCs

-Effect of Sunitib
assessed in vitro on
MDSC from
peripheral blood

Among 18 patients,
there were 1 complete
response, no partial
responses, 11 stable
diseases and 3
progression. 3 patients
had IL-2 treatment
discontinued.
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Targeting of tumor
cells and immune
cells (T cells,
MDSC)

Sunitinib (tyrosine
kinase inhibitor)
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PBMCs; RCC

(222, 223,
225, 226)

RATIONALE, SIGNIFICANCE AND MAIN FINDINGS
Chemotherapeutic protocols already established in the clinic mainly include drugs that
target tumor cell proliferation and induce tumor cell death. The success of current
chemotherapeutic protocols in the clinic has been limited due to the ability of cancer cells
to develop resistance and evade immunesurvaillance. MDSC have been widely described
in the literature and it is currently accepted that targeting MDSC in the clinic is vital for
the development of effective anti-tumor immunity.One of the main challenges in MDSC
research is its heterogeneity and the absence of a universal marker for immunosuppression.
The availability of a wide spectrum of markers to describe different MDSC subsets in mice
and the absence of a Gr-1 homologue in humans have limited the success of MDSC
targeting in the clinic. The absence of unique markers has led to the lack of consensus in
the literature, especially in human subject studies. In addition, due to limitations in the
acquisition of tumor tissue from cancer patients, most studies describing MDSC
phenotype, suppressive activity and response to therapeutic treatment in human cancer
patients are restricted to the peripheral blood. Current data from tumor-bearing mice and
clinical trials have revealed MDSC plasticity, with discripancies in the responses to therapy
between tumor-infiltrating MDSC and peripheral MDSC (e.g. spleens of tumor-bearing
mice, peripheral blood of cancer patients). The presence of tumor-infiltrating MDSC in the
tumor microenvironment has rendered it more resistant to therapy in the clinic.
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The introduction of immunomodulatory agents with no side-effects and at a low cost
have been a challenge in the clinic. In this study, we provide evidence that particulate βglucan has immunolomodulatory functions on MDSC. Particulate β-glucan is a natural
compound, can be provided at a low-cost, ingested orally and with no reported sideeffects.We herein demonstrate that particulate β-glucan differentiallly modulate the
function of M-MDSC and PMN-MDSC subsets. First, we show that particulate β-glucan
induce a cytotoxic phenotype in PMN-MDSC and subsequent apoptosis through dectin-1
signaling. Second, we demonstrate that particulate β-glucan induces M-MDSC
differentiation into antigen-presenting cells in a dectin-1 dependent manner. Third, we
are the first to highlight the effect of particulate β-glucan treatment in patients with
NSCLC, by demonstrating that the frequency of MDSC in the peripheral blood of these
patients decreased in two weeks after treatment. These findings support the
administration of particulate β-glucan as a form of adjuvant therapy in the clinic.
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Figure 4. Schematic model showing how particulate β-glucan modulates MDSC
function. Particulate β-glucan binds to dectin-1 receptor on M-MDSC inducing its
differentiation to F4/80+CD11c+ cells with upregulated expression of CD86, MHCI,
MHCII and CD40 enhancing the synaptic potential between M-MDSC and T cells for
antigen-presentation. M-MDSC upon particulate β-glucan engagement convert to potent
APC that cross-present antigen to antigen-specific CD8+ T cells and present antigen to
CD4+ T cells, which produce Granzyme B and IFN-γ, leading to a cytolytic response loop
against tumor cells. On the other hand, particulate β-glucan activates PMN-MDSC
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respiratory burst and subsequent apoptosis in a dectin-1 dependent manner. Therefore,
providing a pool of ROS upon PMN-MDSC priming, that may negatively impact tumor
cell growth.
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MATERIALS AND METHODS
Mice and tumor models
Wildtype (WT) C57BL/6 mice were purchased from the National Cancer Institute (NCI).
Dectin-1 KO mice were described previously (120, 259). OT-I Rag1-/- and OT-II CD4
ovalbumin TCR-Tg mice were purchased from Taconic.
Tumor models and particulate β-glucan therapeutic protocol were performed as described
previously (49). Briefly, C57BL/6 WT or dectin-1 KO mice were implanted
subcutaneously (s.c.) with Lewis Lung Carcinoma (LLC) (2x105/mouse) or mammarycell carcinoma (E0771) cell lines (6x105/mouse). On day 8 post-implantation, mice with
palpable tumors were orally administered daily by gavage with 100 µl particulate βglucan (Biothera, 800 μg/mouse in PBS suspension) or with 100μl PBS. Tumor diameters
were measured with a caliper every three-four days, and mice were killed when the tumor
diameter reached 15mm. The tumor volume was calculated based on the formula=length
x width2/2. The protocols on murine tumor models were performed according to the
institutional guidelines and laws, and were approved by the Institutional Animal Care and
Use Committee at the University of Louisville.
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Single-cell suspensions from tumors
Mouse tumor tissues (12-15 mm in diameter) were excised and minced into small pieces.
Additional mechanical digestion was performed with gentleMACS dissociator (Milteneyi
Biotec). Tumors were enzymatically digested in RPMI 1640 medium containing 10%
FBS, type IV collagenase (1 μg/ml) and hyaluronidase (10 ng/ml) for 45 minutes at 37oC
on a rotator. A second step of mechanical dissociation was performed after enzymatic
digestion. The digested cells were then filtered, pelleted and re-suspended in complete
RPMI.
Flow Cytometry and Cell Sorting
Single-cell suspensions were treated with Fc-blocker for 10 min on ice and stained with
the relevant fluorochrome-labeled mAbs for 30 min on ice. Cells were washed 2X with
PBS or staining buffer (PBS+0.1%FBS) (for FACS analysis) or running buffer
(Milteney) (for cell sorting). For FACS analysis, cells were acquired using FACS Calibur
or FACS Canto II (BD biosciences). MDSC were sorted using BD FACSAria III cell
sorter or MoFlo XDP (Beckman Coulter). The purity of sorted cells was >98% assessed
by flow cytometry. For intracellular staining of IFN-γ and granzyme B, cells were first
stained with either anti-CD4 or anti-CD8 Abs, fixed, permeabilized with
Fixation/permeabilization buffer (Biolegend), washed with 1X permeabilization/washing
buffer (Biolegend) and stained with the relevant cytokine Abs. Cells were then washed
2X with 1X perm/washing buffer and analyzed by flow cytometry. Data analysis was
performed using FlowJo software (Tree Star). The following fluorochrome-labeled
monoclonal antibodies were used: anti-mouse Gr-1, anti-mouse Ly6G, anti-mouse Ly6C,
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anti-mouse CD11b, anti-mouse CD45, anti-mouse F4/80, anti-mouse CD11c, anti-mouse
CD40, anti-mouse CD86, anti-mouse CD80, anti-mouse IA/IE, anti-mouse H2-Kb, antiCD8, anti-CD4, anti-IFN-γ, anti-GranzymeB and their corresponding isotype controls
were purchased from Biolegend. The following anti-human monoclonal antibodies: antiCD11b, anti-CD14, anti-CD33, anti-HLA-DR, anti-CD3 anti-IFN-γ with their
corresponding isotype controls were also purchased from Biolegend.
Apoptosis assays
Splenocytes from LLC-bearing C57BL/6 or Dectin-1-/-mice were stimulated with WGP
for 3, 6, 14, or 18 hours and then stained with anti-Gr-1 and anti-CD11b Abs (Biolegend)
and 7AAD and Annexin V dyes (BD biosciences). Cells were analyzed by flow
cytometry.
Respiratory Burst assays
Sorted PMN-MDSC from WT or Dectin-1-/- mice were stained with dihydrorhodamine
(DHR) 123 as described previously (260, 261). Briefly, cells were incubated with 1μM
DHR and catalase for 5 min at 37oC. Particulate β-glucan was then added for 30 min, 60
min and 120 min. Rhodamine (RHO) was then detected on FL-1 channel on a FACS
Calibur or FACS Canto II.
Western Blot analysis
Sorted M-MDSC or PMN-MDSC stimulated with or without particulate β-glucan (100
μg/ml) for indicated times were lysed in Triton X-100 lysis buffer in the presence of
protease and phosphatase inhibitor. The whole cell extracts were subjected to SDS-PAGE
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and electro-transferred to PDVF membrane. The membranes were blocked and probed
overnight at 4oC with the relevant primary and then incubated for 1 hour at room
temperature with the secondary Abs. The blots were developed with ECL Plus Western
Blotting Detection Reagents (GE Healthcare). The primary Abs included: p-Erk1/2
(Thr202/Tyr204, Cell Signaling). Erk1/2 (MK1, Santa Cruz), p-Stat3 (Tyr705, Cell
Signaling), p-AKT (Ser473, Cell Signaling), p-p38 (Thr180/Tyr182, Cell Signaling), pZap/Syk (Tyr319/Tyr352, Cell Signaling), STAT3 (C-20, Santa Cruz), p-SAPK/JNK
(Thr183/Tyr185, Cell Signaling) and β-actin (Sigma-Aldrich).
Monocytic-MDSC (M-MDSC) differentiation assay
M-MDSC (CD11b+Ly6ChighLy6G-) were sorted from the spleens of LLC-bearing WT or
dectin-1 KO mice and cultured for 7 days with 50µg/ml particulate β-glucan in 48-well
plates (corning).
T cell proliferation and Ag-presentation assays
For T cell proliferation assay, M-MDSC and PMN-MDSC sorted from the spleens or Gr1+CD11b+ MDSC from tumors of LLC-bearing mice, were co-cultured with 1μM
carboxyfluorescin dye (CFSE)-labeled splenocytes from OT-II or OT-I mice in the
presence of OVA (100 µg/ml in OT-II cultures, 50µg/ml in OT-I cultures, and 10 µg/ml
in some splenic PMN-MDSC suppression experiments) and particulate β-glucan (50
μg/ml). Three days later, cells were harvested and stained. In addition, some T cell
proliferation assays were performed by co-culturing sorted MDSC with CFSE-labeled
splenocytes from C57BL/6 mice stimulated with plate-bound anti-CD3 (5 μg/ml) and
soluble anti-CD28 (2 μg/ml).
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For Ag-presentation assay, sorted M-MDSC from the spleens of LLC-bearing WT or
dectin-1 KO mice were cultured in the presence or absence of particulate β-glucan
(50μg/ml) for 7 days. In some experiments, MEK1/2 inhibitor (PD98059) (30 ng/ml) or
DMSO was added to cultures during differentiation. Cells were washed and co-cultured
with sorted and CFSE-labeled CD8+ or CD4+ T cells from OT-I and OT-II mice,
respectively, in the presence or absence of whole OVA-Ag (50 μg/ml). T cell
proliferation and IFN-γ or granzyme B production were assessed 4-5 days later by flow
cytometry.
RNA extraction and Quantitative Real-Time PCR (qRT-PCR)
RNA was extracted with Trizol reagent (Invitrogen) as described in the manufacturer
protocols. Extracted RNA was transcribed to cDNA with a Reverse Transcription Kit
(Bio-Rad). qRT-PCR reaction was performed using SYBR Green Supermix (Bio-Rad)
with the relevant primers (Table 3) and the reaction was detected on MyiQ single color
RT-PCR detection system (Bio-Rad). The change in gene expression was quantified by
measuring the change in threshold (ΔΔCT), where ΔCt= Ct target gene-Ct House keeping gene and
ΔΔCt= ΔCt induced- ΔCt reference.
In vivo M-MDSC/LLC admixture experiments
Sorted M-MDSC were treated with or without particulate β-glucan for 18 hours and
mixed with LLC cells (1x105) at a 1:1 ratio. Cells were mixed with Matrigel® Matrix
Basement membrane (Corning) and implanted subcutaneously in the flanks of C57BL/6
mice. Tumor diameter was measured every two days and mice were sacrificed on day 25.
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Human subjects
NSCLC patients that were newly diagnosed, received particulate β-glucan treatment at
the James Graham Brown Cancer Center, University of Louisville. These patients did not
receive any other treatment prior or during β-glucan treatment. The study was approved
by the Institutional Ethical Board and blood samples were collected upon a written
informed consent. Each NSCLC patient received 500 mg of particulate β-glucan for 1014 days. Peripheral blood was collected before and after treatment. Whole blood cells
were treated with ACK lysis buffer, washed 2X with PBS and stained with human antiCD14, anti-HLA-DR, anti-CD11b and anti-CD33 Abs (Biolegend) for 30 min on ice.
Samples were then washed 2X prior to acquisition on FACS Calibur. Neutrophils were
purified with a histopaque density gradient and stored into Trizol at -80oC for RNA
extraction (105).
Mixed lymphocyte reaction (MLR)
CD14+ HLA-DR+ CD3- or CD14-HLA-DR-CD11b+CD33+CD3- cells were sorted from
the PBMCs of NSCLC patients and co-cultured with sorted and CFSE-labeled CD3+
cells from the PBMCs of allogeneic donor at 1:1 ratio for 5 days. Cells were then
harvested and stained with human anti-CD3 and human anti-IFN-γ mAbs for subsequent
flow cytometry analysis.
Statistical analysis
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Data were analyzed using GraphPad Prism (5.0) software. Unpaired student t-test was
used to calculate significance. Significance was assumed to be reached at p<0.05. All
graph bars are expressed as mean ± SEM.
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Table 3. Primer sequences used in qRT-PCR analysis of different mRNA expression
used in this study.
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RESULTS

PMN-MDSC preferentially expand in the spleens and tumors during tumor
progression

In order to characterize the abundance of MDSC populations during tumor progression
before β-glucan treatment, we subcutaneously implanted mice with Lewis Lung Carcinoma
(LLC), mammary carcinoma (E0771) and B16 F10 melanoma. And then assessed the
frequency of different MDSC subsets in the spleen and tumor of tumor-bearing mice at
different tumor sizes. The groups are described as follows: naïve mice, small tumors (58mm), medium tumors (9-12mm) and large tumors (12-15mm). Despite many studies
describing the expansion of MDSC during tumor progression (40), we sought to ensure
first that MDSC expansion positively correlates with tumor progression in the three animal
models tested, to then study the effect of particulate β-glucan on MDSC frequencies.
Indeed during tumor progression, PMN-MDSC preferentially expand in the spleens
(Figure 5) and tumors (Figure 6) of tumor-bearing mice.

PMN-MDSC are

CD45+CD11b+Ly6G+Ly6Cint and M-MDSC are CD45+CD11b+Ly6G-Ly6Chigh (Figure 7).
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Figure 5. Kinetics of MDSC frequencies in the spleens of tumor-bearing mice during
tumor progression. Pie-graph demonstration of PMN-MDSC and M-MDSC frequencies
in the spleens of tumor-bearing mice implanted with B16 F10 melanoma (n=8, 2 mice per
group), E0771 (n=18, 5 mice per group except the large tumor group n=3), and LLC (n=19,
5 mice per group except the large tumor group n=4). Naïve mice were mice not implanted
with tumors. The tumor sizes are: small: 5-8 mm; medium:9-12 mm; large: 12-15 mm.
Mice of different groups were injected at different days to ensure that mice implanted with
one tumor cell line be killed in the same day.
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Figure 6. Kinetics of MDSC frequencies in the tumors of tumor-bearing mice during
tumor progression. Pie-graph demonstration of PMN-MDSC and M-MDSC frequencies
in the spleens of tumor-bearing mice implanted with B16 F10 melanoma (n=4, 1 mouse
representing the large tumor, 1 mouse the medium tumor and 2 mice the small tumors),
E0771 (n=13, 5 mice per group except the large tumor group n=3), and LLC (n=14, 5 mice
per group except the large tumor group n=4). Naïve mice were mice not implanted with
tumors. The tumor sizes are: small: 5-8 mm; medium:9-12 mm; large: 12-15 mm. Mice of
different groups were injected at different days to ensure that mice implanted with one
tumor cell line be killed in the same day.
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Figure 7. Representative dot plots of MDSC in tumor during tumor progression in
LLC, E0771 and B16-bearing mice. MDSC in tumor-bearing mice consist of mainly two
heterogenous subsets: polymorphonuclear (PMN-MDSC) and monocytic (M-MDSC).
PMN-MDSC are CD45+CD11b+Ly6G+Ly6Cint and M-MDSC are CD45+CD11b+Ly6GLy6Chigh.
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Particulate β-glucan oral treatment diminishes tumor growth and differentially
impacts the frequency of MDSC subsets in spleens and tumors
To delineate the effect of particulate β-glucan treatment on the composition of different
MDSC subsets in spleens and tumors, C57BL/6 mice were challenged with LLC and
E0771 cell lines subcutaneously. Mice with palpable tumors were administered orally
through gavage with PBS or particulate β-glucan (WGP) as previously established (49,
130). β-Glucan treatment significantly reduced tumor volumes (Figure 8A), splenomegaly
(Figure 8B. ), and tumor weight (Figure 8C) in both models. When analyzing the
frequencies of MDSC subsets in the spleens and tumors, particulate β-glucan-treated mice
had a significant decrease in PMN-MDSC frequencies in the spleen, but not M-MDSC, in
both models (Figure 9). In addition, particulate β-glucan treatment caused a significant
decrease in the frequencies of PMN-MDSC and increase in the frequencies of M-MDSC
in the tumors of E0771 mice, but only trending in LLC-bearing mice (Figure 10).
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Figure 8. Particulate β-glucan treatment in vivo reduces tumor burden and
splenomegaly. (A) C57BL/6 WT mice (n=7, 8) were injected subcutaneously (s.c) with
LLC or E0771 tumor cell lines. Once palpable tumors were formed (day 8), mice were
orally administered with particulate β-glucan (800 μg, daily) or PBS with a gavage needle
at indicated time. Tumor diameters were measured every three days and tumor volumes
were then calculated. (B) On day 32 (LLC model) or day 35 (E0771 model), mice were
killed and spleens were excised and weighed. Each point in the data plot represents the
spleen weight of each mouse in grams. PBS-treated group was compared to particulate βglucan treated group (WGP) in both models (C) Tumor tissues were excised and
weighted from WGP or PBS-treated mice. *p<0.05, ** p<0.01, *** p<0.001.
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Figure 9. Particulate β-glucan treatment in vivo impacts the frequency of MDSC in
spleens and tumors of LLC and E0771-bearing mice. Flow cytometry analysis of the
frequencies of M-MDSC (Ly6G-Ly6Chigh) and PMN-MDSC (Ly6G+Ly6Cint) in the
spleens of LLC and E0771-bearing mice treated with PBS or particulate β-glucan (WGP).
Cells were gated on CD11b+ cells. *p<0.05, ** p<0.01, *** p<0.001.
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Figure 10. Particulate β-glucan treatment in vivo reduces PMN-MDSC but not MMDSC frequency in tumor-bearing mice. Frequencies of M-MDSC and PMN-MDSC in
the tumors of LLC and E0771-bearing mice treated with PBS or particulate β-glucan (WGP).
Cells were gated on CD45+CD11b+ cells. *p<0.05, ** p<0.01, *** p<0.001.
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Particulate β-glucan treatment abolishes splenic and tumor MDSC-mediated T cell
suppression
Since suppression of CD8+ effector T cells in tumor-bearing mice is largely attributed to
MDSC (262, 263), we thought to determine whether particulate β-glucan impacts T cell
suppression mediated by splenic and tumor MDSC. To this end, we studied the effect of
particulate β-glucan treatment on MDSC-mediated inhibition of OVA-specific CD4+ and
CD8+ T cells or Ag non-specific T cell proliferation induced by anti-CD3/CD28
stimulation. Suppression of OVA-specific CD4+ T cells mediated by splenic M-MDSC or
PMN-MDSC was partially or completely obliterated upon particulate β-glucan treatment
(Figure 11A). Similarly, particulate β-glucan treatment significantly increased the
proliferation of OVA-specific CD8+ T cells in the presence of suppressive M-MDSC or
PMN-MDSC (Figure 11B). Particulate β-glucan treatment also diminished the MDSCmediated suppression of IFN-γ produced by OVA-specific CD4+ (Figure 12A) and CD8+
T cells (Figure 12B). In addition, particulate β-glucan treatment decreased the ability of
M-MDSC to suppress CD4+ T cells and CD8+ T cells stimulated with anti-CD3/CD28 (Fig
13). However, splenic PMN-MDSC did not suppress the proliferation of T cells stimulated
with anti-CD3/CD28, as previously reported (32). To generalize the efficacy of particulate
β-glucan on the modulation of MDSC suppression, tumor Gr-1+CD11b+ cells were also
sorted from LLC tumors and co-cultured with OVA-specific CD4+ or CD8+ T cells in the
presence of OVA at different ratios. While Gr-1+CD11b+ MDSC suppressed the
proliferation and IFN-γ production of CD4+ T cells (Figure 14A) and CD8+ T cells (Figure
15), particulate β-glucan treatment significantly enhanced T cell proliferation and IFN-γ
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production on CD4+ and CD8+ T cells (Figure 14,15). Taken together, these data emphasize
the ability of particulate β-glucan to reverse MDSC-mediated T cell suppression.

Figure 11. Particulate β-glucan in vitro treatment restores IFN-γ production by
antigen-specific T cells co-cultured with MDSC (A) OT-II splenocytes co-cultured with
sorted M-MDSC or PMN-MDSC from the spleens of LLC-bearing mice in the presence of
OVA (100 μg/ml) with or without particulate β-glucan (50 μg/ml) for 3-4 days at 1:1 ratio
and stimulated with PMA/Ionomycin for intracellular IFN-γ staining. Data represent the
percentage of IFN-γ+ cells gated on CD4+ T cells. The experiment was repeated 3 times
77

with similar results. (B) CFSE-labeled OT-I splenocytes co-cultured with sorted M-MDSC
or PMN-MDSC from the spleens of LLC-bearing mice in the presence of OVA (50 μg/ml
in M-MDSC cultures and 10 μg/ml in PMN-MDSC cultures) and particulate β-glucan (50
μg/ml) for 3 days at 1:1 ratio and then stimulated with PMA/Ionomycin for intracellular
IFN-γ staining. Data represent the percentage of IFN-γ+ CFSE diluted cells gated on CD8+
T cells. Results are representative of three independent experiments. * p<0.05, **p<0.01,
***p<0.001.
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Figure 12. Particulate β-glucan treatment in vitro subverts splenic MDSC-mediated
T cell suppression. (A) CFSE-labeled OT-II splenocytes co-cultured with sorted MMDSC or PMN-MDSC from the spleens of LLC-bearing mice in the presence or absence
of particulate β-glucan (100 μg/ml in the M-MDSC cultures and 50 μg/ml in the PMNMDSC cultures) and OVA (100 μg/ml) for 3 days at 1:1 ratio. Data represent the percentage
of CFSE diluted cells gated on CD4+T cells. The experiment was repeated two times with
similar results. (B) CFSE-labeled OT-I splenocytes were co-cultured with sorted M-MDSC
or PMN-MDSC from the spleens of LLC-bearing mice in the presence of OVA (50 μg/ml)
and particulate β-glucan (50 μg/ml) for 3 days at 1:1 ratio. Data represent the percentage
of CFSE diluted cells gated on CD8+ T cells. Data is representative of three independent
experiments. * p<0.05, **p<0.01, ***p<0.001.
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Figure 13. Particulate β-glucan in vitro treatment reverses antigen non-specific
suppression in T cells co-cultured with M-MDSC but not PMN-MDSC. CFSE-labeled
splenocytes from C57BL/6 mice stimulated with plate-bound anti-CD3 (5 μg/ml) and soluble
anti-CD28 (2 μg/ml) (white bar) and co-cultured with sorted splenic M-MDSC or PMN-MDSC
from LLC-bearing mice for 3 days with (black bar) or without particulate β-glucan (50 μg/ml)
(grey bar). Data represent the frequency of CFSE diluted cells gated on CD4 + or CD8+ T cells.
The experiment was repeated twice with similar results. * p<0.05, **p<0.01, ***p<0.001.
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Figure 14. Particulate β-glucan reduces tumor Gr-1+CD11b+ MDSC-mediated
suppression of IFN-γ production by OVA-specific CD4+ T cells. (A) Tumor Gr1+CD11b+CD45+ MDSC sorted from LLC-bearing mice were co-25 cultured with CFSElabeled OT-II splenocytes at indicated ratios, in the presence of OVA (100 μg/ml) with or
without particulate β-glucan (50 μg/ml) for 3-4 days. Data represent the frequency of CFSE
diluted cells gated on CD4+ T cells. The experiment was repeated twice with similar
results. (B) Same cell cultures as (A) were further stimulated with PMA/Ionomycin for
intracellular IFN-γ staining. The experiment was repeated twice with similar results. *
p<0.05, **p<0.01, ***p<0.001.
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Figure 15. Particulate β-glucan restores IFN-γ production by OVA-specific CD8+ T
cells co-cultured with tumor Gr-1+CD11b+ MDSC. Splenocytes of OT-I mice were cocultured with sorted Gr-1+CD11b+CD45+ tumor MDSC from LLC-bearing mice at indicated
ratios, in the presence of OVA (50 μg/ml in M-MDSC cultures and 10 μg/ml in PMN-MDSC
cultures) with or without particulate β-glucan (50 μg/ml). Data represent the percentage of
IFN-γ+ cells and CFSE diluted cells gated on CD8+ T cells. Results are representative of two
independent experiments. *p<0.05, **p<0.01, ***p<0.001.
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Dectin-1 stimulation with particulate β-glucan induces PMN-MDSC respiratory
burst and apoptosis via the dectin-1 signaling
Given that WGP treatment reduced PMN-MDSC-mediated T cell suppression and
decreased PMN-MDSC frequency in the spleens and tumors of tumor-bearing mice, we
tested whether particulate β-glucan treatment has a further impact on PMN-MDSC
viability. Particulate β-glucan treatment enhanced PMN-MDSC apoptosis at 3 hours, 6
hours and more drastically at 14 and 18 hours post-stimulation (Figure 16A). PMN-MDSC
apoptosis was mediated by dectin-1 receptor since particulate β-glucan did not induce
PMN-MDSC apoptosis in PMN-MDSC sorted from the spleens of LLC-bearing dectin-1
knockout mice (Figure16B). Since particulate β-glucan-induced apoptosis is more drastic
at late-time points, we asked whether particulate β-glucan treatment enhances PMNMDSC respiratory burst, a hallmark of neutrophil-mediated cytotoxicity. We detected
PMN-MDSC respiratory burst by dihydrorhodamine 123 (DHR) dye that oxidizes to
fluorescent rhodamine 123 (RHO) in the presence of intracellular ROS (261). Upon
particulate β-glucan stimulation, PMN-MDSC respiratory burst was significantly enhanced
upon 1 hour and 2 hours post-stimulation (Figure 17). To exclude the effect of dectin-1
independent phagocytosis on the induction of PMN-MDSC respiratory burst, we
stimulated PMN-MSDC from dectin-1 knockout mice with particulate β-glucan. As
expected, particulate β-glucan stimulation did not induce respiratory burst in dectin-1
knockout PMN-MDSC (Figure 17).
Previous studies have highlighted the importance of STAT3 phosphorylation in the
cascade events mediating PMN-MDSC survival and suppression (38). Since particulate β83

glucan treatment abrogated PMN-MDSC mediated T cells suppression and induced PMNMDSC apoptosis, we measured STAT3 phosphorylation at 15, 30 and 60 min poststimulation. STAT3 phosphorylation was inhibited after 15 min and completely abrogated
after 30 min upon β-glucan stimulation (Figure 18). This effect was mediated by dectin-1
signaling, since particulate β-glucan stimulation enhanced Syk phosphorylation. Moreover,
particulate β-glucan stimulation enhanced phosphorylation of molecules downstream of
the dectin-1 receptor such as Akt, JNK and Erk1/2 kinases but not p38 (Figure 18).
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Figure 16. Particulate β-glucan induces apoptosis in PMN-MDSC in a dectin-1
dependent manner. (A) Representative dot plots showing the frequency of annexin V+
cells gated on Gr-1highCD11b+ PMN-MDSC in splenocytes of LLC-bearing mice
cultured with media only or with particulate β-glucan (100 μg/ml) for indicated time.
Summarized data are also shown (n=8). (B) Frequencies of annexinV+ cells gated on Gr1high CD11b+ PMN-MDSC from WT or dectin-1 KO LLC-bearing mice cultured for
18hours with or without particulate β-glucan (100 μg/ml) (n=2). *p<0.05,
**p<0.01,***p<0.001.
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Figure 17. Particulate β-glucan induces respiratory burst in PMN-MDSC in a
dectin-1 dependent manner. Respiratory burst in PMN-MDSC sorted from spleens of
LLC-bearing WT or dectin-1 KO mice stimulated with particulate β-glucan (100 μg/ml)
for indicated time. Reduction of dihydrorhodamine 123 (DHR) to fluorescent rhodamine
123 (RHO) was assessed by flow cytometry. Data is representative of 6 independent
experiments (WT) and two independent experiments (KO).
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Figure 18. Particulate β-glucan inhibits p-STAT3 phosphorylation and enhances
MAPK signaling in PMN-MDSC. Western blot analysis of p-STAT3, p-Zap/Syk, pAkt, p-SAPK/JNK, p-Erk1/2, p-p38, STAT3 and β-actin in PMN-MDSC sorted from the
spleens of LLC-bearing mice and treated with particulate β-glucan (100 μg/ml) for 0, 15,
30 and 60 minutes. Results are representative of at least three independent experiments.
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Particulate β-glucan treatment fully converts M-MDSC to potent APC
Previous studies have demonstrated the ability of particulate β-glucan to enhance dendritic
cell Ag-presenting capability (130), and that 8-13% of M-MDSC cultured with particulate
β-glucan and GM-CSF are F4/80+CD11c+ (50). To further determine the effect of
particulate β-glucan on M-MDSC, we solely treated M-MDSC with particulate β-glucan
in the absence of GM-CSF for 5 days or 7 days and assessed the expression of F4/80,
CD11c, CD11b, Gr-1, CD80, CD86, MHC class I, MCH class II and CD40. The majority
of M-MDSC cultured with particulate β-glucan for 7 days differentiated to
F4/80lowCD11c+CD11b+Gr1- cells and expressed CD86, CD80, MHC class II, MHC class
I and CD40 (Figure 19A and B), cells were viable (trypan-blue exclusion) and 7AAD- (data
not shown).
It has been proposed that MDSC can uptake, process and present Ag, establishing a stable
synapse with T cells required for Ag-specific T cell suppression (264). Freshly isolated
splenic M-MDSC cultured with sorted OVA-specific CD4+ T cells in the presence of OVA
did not induce CD4+ T cell proliferation or IFN-γ production (Figure 20). To test whether
M-MDSC co-cultured with particulate β-glucan for 7 days differentiated to potent APC,
we co-cultured M-MDSC with particulate β-glucan for 7 days and then cultured with sorted
and CFSE-labeled OVA-specific CD4+ T cells in the presence of whole OVA Ag for 4-5
days. Differentiated M-MDSC induced CD4+ T cell proliferation and IFN-γ production
(Figure 21). Moreover, differentiated M-MDSC cross-presented Ag to OVA-specific CD8+
T cells and immensely induced CD8+ T cell proliferation and cytokines associated with
effector functions such as IFN-γ and Granzyme B (Figure 22). Taken together, these data
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clearly demonstrate that particulate β-glucan converts suppressive M-MDSC to potent
APC that can promote Th1 differentiation and Ag cross-presentation to CD8+ effector T
cells.
Dectin-1 receptor signaling is required for the conversion of M-MDSC to potent APC
To exclude the possibility of any artifacts in M-MSDC differentiation that might be
promoted by particulate β-glucan phagocytosis alone and to test whether it is directed by
dectin-1 receptor, we performed Ag presentation assays with wild-type or dectin-1 KO MMDSC pretreated with particulate β-glucan for 7 days. WT M-MDSC but not dectin-1 KO
M-MDSC induced OVA-specific CD4+ T and CD8+ T cell proliferation and IFN-γ
production (Figure 23). In addition, particulate β-glucan stimulation enhanced the
phosphorylation of Syk, Akt, JNK and Erk1/2 but not p38 (Figure 24). Surprisingly,
STAT3 phosphorylation was enhanced after particulate β-glucan stimulation, opposite
from PMN-MDSC. Pretreatment of M-MDSC with WGP in the presence of MEK1/2
inhibitor (PD98059) abrogated the acquired Ag-presenting capability of differentiated MMDSC (Figure 25). In addition, M-MDSC treated with particulate β-glucan for 7 days
increased the expression of TNF-α, IL-12, iNOS and IL-6, and decreased TGF-β compared
to freshly sorted M-MDSC (Figure 26). Enhancement of TNF-α and IL-12 mRNA
expression was completely abrogated in dectin-1 KO M-MDSC upon particulate β-glucan
stimulation (data not shown).

89

Figure 19. Particulate β-glucan induces M-MDSC differentiation and the expression
of costimulatory molecules. (A) Expression of CD11c, F4/80 and CD11b surface markers
on M-MDSC cultured with particulate β-glucan (50 μg/ml) for 0, 5 and 7 days. Results
were repeated at least three times with similar results. (B) Expression of Gr-1, CD80,
CD86, MHC class II, MHC class I, and CD40 surface markers on M-MDSC cultured with
particulate β-glucan (50 μg/ml) for 7 days. Histograms represent the results of three
independent experiments.
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Figure 20. M-MDSC do not present Ag to CD4+ T cells. Frequency of IFN-γ+ CFSEgated on CD4+ T cells in cultures where freshly sorted M-MDSC from the spleens of LLCbearing mice were incubated for 5 days with CFSE-labeled CD4+ T cells in the presence
of OVA (100μg/ml). Splenocytes were used as APC positive control.
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Figure 21. Differentiated M-MDSC with particulate β-glucan present OVA Ag to
OVA-specific CD4+ T cells. Sorted and CFSE-labeled CD4+ OT-II T cells were cocultured with splenic M-MDSC pre-cultured with particulate β-glucan for 7 days in the
presence of OVA (50 μg/ml) for 4-5 days. The frequencies of CFSE diluted cells and IFNγ+ CD4+ T cells were shown. Splenocytes were used as APC positive control. The results
are representative of at least four independent experiments. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
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Figure 22. Differentiated M-MDSC with particulate β-glucan present OVA Ag to
OVA-specific CD8+ T cells. Sorted and CFSE-labeled CD8+ OT-I T cells were cocultured for 4-5 days with OVA (50 μg/ml) and splenic M-MDSC pre-cultured with
particulate β-glucan for 7 days. The frequencies of CFSE diluted cells, IFN-γ+ cells and
Granzyme B+ cells gated on CD8+ T cells are demonstrated. Results are representative of
two independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 23. Particulate β-glucan-induced M-MDSC antigen-presenting function is
dectin-1 dependent. (A) CD4+ and CD8+ T cells were sorted from OT-II and OT-I mice,
respectively, CFSE-labeled and co-cultured for 4-5 days with M-MDSC sorted from the
spleens of WT or dectin-1 KO LLC-bearing mice. M-MDSC were pre-treated with
particulate β-glucan for 7 days prior to co-culture with CD4+ or CD8+ T cells. The
frequency of CFSE-IFN-γ+, gated on CD4+ T cells (upper panel) or CD8+ T cells (lower
panel), are represented in the dot plots. Results are representative of two-independent
experiments. *p<0.05, **p<0.01.
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Figure 24. Particulate β-glucan induces p-STAT3 and Syk downstream dectin-1 in MMDSC. Western blot analysis of p-STAT3, p-Zap/Syk, p-Akt, p-SAPK/JNK, p-Erk1/2, pp38, STAT3 and β-actin in M-MDSC sorted from the spleens of LLC-bearing mice and
stimulated with particulate β-glucan (100 μg/ml) for 0, 15, 30 and 60 minutes.
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Figure 25. Particulate β-glucan induces M-MDSC differentiation to APC in an
Erk1/2-dependend manner. CD4+ T cells sorted from OT-II mice were CFSE-labeled
and co-cultured with OVA and M-MDSC pre-treated with particulate β-glucan in the
presence of MEK1/2 inhibitor (PD98059) (30 ng/ml) or DMSO for 7 days. Data
demonstrate the frequencies of CFSE diluted cells and IFN-γ+ cells gated on CD4+ T cells.
Results are representative of two independent experiments.
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Figure 26. Differentiated M-MDSC express pro-inflammatory cytokines upon
particulate β-glucan treatment. The relative mRNA expression of TNF-α, IL-12, iNOS,
IL-6, and TGF-β in MDSC, sorted from the spleens of LLC-bearing mice, and incubated
with particulate β-glucan for 7 days compared to its expression in freshly sorted M-MDSC.
*p<0.05, **p<0.01, ***p<0.001.
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Particulate β-glucan-treated M-MDSC do not enhance tumor growth and
development in vivo
To evaluate the effect of particulate β-glucan-treated M-MDSC on tumor development
in vivo, we performed admixture experiments with M-MDSC/tumor cells. LLC cells were
mixed with M-MDSC or M-MDSC treated with particulate β-glucan for 18 hours at a 1:1
ratio, and injected subcutaneously into C57BL/6 mice. M-MDSC but not particulate βglucan-treated M-MDSC induced tumor progression and growth compared to LLC alone
(Figure 27A). In addition, LLC/M-MDSC tumors had a significantly higher weight
compared to tumors implanted with LLC/ particulate β-glucan-treated M-MDSC (Figure
27B).
Particulate β-glucan treatment reduces the frequency of HLA-DR-CD14CD11b+CD33+ MDSC in the peripheral blood of NSCLC patients
To imply the significance of the current findings into human patients, we conducted a
particulate β-glucan clinical trial in patients with non-small cell lung cancer (NSCLC) that
were newly diagnosed and had not received any treatment. Particulate β-glucan was
administered orally for two weeks at 500 mg dose and blood was withdrawn before and
after treatment. Consistent with previous studies (40, 41), the frequency of HLA-CD14CD33+CD11b+ MDSC was substantially increased in the peripheral blood of patients with
NSCLC compared to those in age and sex matched healthy donors (Figure 28). Particulate
β-glucan treatment significantly reduced the percentage of HLA-DR-CD14-CD33+CD11b+
MDSC in the peripheral blood of NSCLC patients when compared to its frequency in the
peripheral blood before treatment (Figure 29).
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Next, we sought to determine the Ag-presenting capability of CD14+HLA-DR+ monocytes
and CD14-HLA-DR-CD11b+CD33+ MDSC in a mixed lymphocyte reaction as previously
described (265). CD14+ HLA-DR+ monocytes significantly induced the proliferation and
IFN-γ production of allogeneic T cells, whereas CD14- HLA-DR-CD11b+CD33+ MDSC
induced minimal response (Figure 30). Next, we sought to assess the effect of particulate
β-glucan treatment on the Ag-presenting capability of CD14+HLA-DR+ monocytes and
CD14-HLA-DR-CD11b+CD33+ MDSC from NSCLC patients. Particulate β-glucan
treatment induced an enhanced trend in proliferation and IFN-γ production by allogeneic
T cells in both populations (Figure 31). In addition, IFN-γ production by T cells from
patients after treatment were also trending enhanced although it did not reach statistical
significance (data not shown).
In NSCLC, Arginase 1 expression was reported to be expressed by CD14-CD11b+CD33+
SSChigh PMN-MDSC (41, 266). To assess the effect of particulate β-glucan treatment on
the function of PMN-MDSC, we compared the expression of Arginase 1 mRNA in the
PMN-isolated from the peripheral blood of NSCLC patients before and after particulate βglucan treatment. The expression of Arginase 1 mRNA was significantly decreased in a
cohort of 15 patients, and became comparable with Arginase 1 mRNA expression in
healthy controls (Figure 32 left panel), whereas it did not significantly change in the other
cohort of 20 patients (Figure 32 right panel). Overall, NSCLC patients have a decreased
frequency of CD14-HLA-DR-CD11b+CD33+ MDSC with improved allogeneic effector T
cell responses after particulate β-glucan treatment.
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Overall we delineated the effect of particulate β-glucan treatment on MDSC from tumorbearing mice (Figure 33) and assessed the in vivo effect of particulate β-glucan treatment
in NSCLC patients.

Figure 27. Particulate β-glucan-treated M-MDSC do not promote tumor progression
when co-implanted with tumor cells in vivo. (A) Splenic M-MDSC sorted from LLCbearing mice treated with or without particulate β-glucan (100 μg/ml) for 18 hours were
mixed with LLC cells at 1:1 ratio and co-implanted s.c. in C57BL/6 mice in matrigel (n=6).
Tumors were measured every two days and mice were sacrificed on day 25 postinoculation. Tumor volumes are shown. (B) Tumor weight (grams) from mice injected with
LLC or LLC+M-MDSC or LLC+M-MDSC treated with WGP. *p<0.05, **p<0.01,
***p<0.001.
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Figure 28. MDSC frequency is enhanced in the peripheral blood of patients with
NSCLC compared to healthy donors. Frequency of CD33+CD11b+ MDSC gated on
CD14-HLA-DR- cells in the peripheral blood of NSCLC patients (n=21) compared to age
and sex matched healthy donors (n=13). **** p<0.0001.
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Figure 29. Particulate β-glucan treatment decreases the frequency of MDSC in the
peripheral blood of NSCLC patients. Frequency of CD33+CD11b+ MDSC gated on
CD14-HLA-DR- cells in the peripheral blood of NSCLC patients 28 before and after
particulate β-glucan treatment for 14 days (n=22). *p<0.05.
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Figure 30. CD14+ HLA-DR+ but not CD14-HLA-DR-CD11b+CD33+ induce IFN-γ
production and proliferation of allogeneic T cells. IFN-γ production and proliferation
(CFSE diluted cells) of allogeneic T cells (CD3+) cultured at 1:1 ratio with CD14+HLADR+CD11b+CD33+ or CD14-HLA-DR-CD11b+CD33+ sorted from the peripheral blood
of NSCLC patients.
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Figure 31. Particulate β-glucan induces and enhances trend of allogeneic T cell
responses upon co-culture with CD14+ or CD14- cells. IFN-γ production and proliferation
(CFSE diluted cells) of allogeneic T cells (CD3+) cultured at 1:1 ratio with CD14+HLADR+CD11b+CD33+ or CD14-HLA-DR-CD11b+CD33+ isolated from the peripheral blood of
NSCLC patients before and after particulate β-glucan treatment (n=11).

104

Figure 32. Particulate β-glucan treatment decreases the mRNA expression of arginase
1 in PMN from the peripheral blood of 15 patients. Relative Arginase1 mRNA
expression levels in neutrophils (PMN) isolated from the peripheral blood of healthy
controls, and patients with NSCLC before and after particulate β-glucan treatment.
Arginase 1 relative mRNA expression significantly decreased in a cohort of 15 patients,
whereas no significant change was reported in the other 20 patients (total n=35). *p<0.05.
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Figure 33. Dual effect of particulate β-glucan (WGP) on MDSC subsets. Particulate βglucan treatment induces PMN-MDSC cytotoxic phenotype with an enhanced respiratory
burst and subsequent apoptosis. Whereas M-MDSC differentiated to potent APC upon
particulate β-glucan treatment. In both subsets, particulate β-glucan reduces MDSCmediated T cell suppression.
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DISCUSSION
Despite the significant advances in our understanding of how the immune system is
‘programmed’ to fight disease, the generic mechanisms of immunity are still elusive. The
obscurity of the detailed mechanisms by which the immune system functions does not
necessarily imply that our knowledge of how it really works is minimal, but that there is
still many facts to be revealed. An important aspect to be mentioned in this line vis à vis
our study, is the role that the immune system plays in cancer. It was not until 2011 that
Hanahan and Weinberg added ‘evasion of immunological destruction’ by tumor cells as an
‘emerging’ hallmark of cancer (267).
The reductionist view of the tumor as a whole, as an autonomous, uniform and homogenous
entity, is part of the past. It is now well appreciated that alongside with hyperproliferating
and heterogeneous cancer cells, cancer stem cells, endothelial cells, pericytes and
fibroblasts lie the tumor-infiltrating immune cells, and altogether constitute the tumor
microenvironment (267, 268).
Our increased understanding of the mechanisms governing tumor progression has revealed
that tumor-derived factors create a suppressive milieu within the immune cell pool in the
tumor microenvironment driving immune suppression. The idea that immune cells can
have a pro-inflammatory or anti-inflammatory phenotype describes the bipolarity of
immune cells and their plasticity (269-271). However, the generalization of the concept of
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the existence of two extreme phenotypes seems imprecise when considering the various
factors present in the tumor microenvironment during different stages of progression that
have the potential to generate a spectrum of activation states in the immune cells (272).
Almost every immune cell has been associated with a regulatory phenotype, among them
are: TAMs (269, 271), regulatory T cells (Treg) (273, 274), tolerogenic DCs (275, 276) ,
NK cellstolerant (277), regulatory B cells (278), regulatory γδ-T cells (165, 166), TANs (161)
and MDSC (33). The notorious phenotype associated with many immune cells in the fight
against tumor maybe challenged by the view that the acquisition of an anti-inflammatory
phenotype in the persistence of Ag or inflammation, is essential for the persistence of the
immune cells for a longer fight. That is, exhaustion might be the shortest metabolic path
for an immune cell to survive in such situation (279), meaning that a continuous evolving
and adapting immune system will pay a price by entering a state of exhaustion in order to
stay alive and in the battle. This radical view implies that the interference with
immunotherapy, in order to succeed, has to be applied at the right time and at the right
phase during disease progression.
Numerous therapeutic agents to target the tumor environment are present in the clinic.
Many of which have not been applied in humans or have been reported to have off target
effects. Our notion of the importance of the usage of natural compounds as potent
biological response modifiers have been increasing with our understanding of the
importance of targeting immune cells that infiltrate the tumor microenvironment. In this
study, the therapeutic agent particulate β-glucan was applied in two animal models of
subcutaneous tumor, mouse lung carcinoma and mammary carcinoma, and in newly
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diagnosed patients with NSCLC. Particulate β-glucan is a natural compound, of low cost
and can be orally ingested.
Previously, we delineated the potent adjuvanticity of natural compound particulate βglucan on T cells through the modulation of DCs (49, 130) and macrophages (unpublished
data).

Recently, it was also reported that particulate β-glucan modulates

immunosuppression by partially inducing the differentiation of M-MDSC in tumor-bearing
mice (50). However, in the latter study the attribution of the decreased in tumor growth to
M-MDSC differentiation was not well-reflected in the in vitro differentiation assays in
which only 8-13% of the cells acquired F480+CD11c+ expression. In addition, the
acquisition of these surface markers does not reflect MDSC functionality, since the only
functional assays performed in the study where in an antigen non-specific system, in which
purified CD4+ T cells where cultured with M-MDSDC pre-treated with particulate βglucan. An enhancement in CD4+ T cell proliferation in these assays can only be attributed
to the effect of particulate β-glucan on soluble factors that mediate MDSC suppression but
not due to the acquisition of APC capability.
Herein, we demonstrate that treatment with yeast-derived particulate β-glucan, reduces
tumor growth and differentially modulates PMN-MDSC and M-MDSC frequencies in
tumor-bearing mice. Especially that we also showed that PMN-MDSC are the main cells
expanding during tumor progression as reported by others (40). Interestingly, particulate
β-glucan had a higher impact on PMN-MDSC frequency compared to M-MDSC. In LLC
and E0771 models, PMN-MDSC frequency significantly decreased in the spleens of
treated animals. Meanwhile it had no effect on M-MDSC frequency. In the same line,
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particulate β-glucan decreased PMN-MDSC while enhanced M-MDSC frequency in the
tumors, suggesting that impacting PMN-MDSC in the spleen alone can cause a systemic
shift towards an anti-tumor immune response (152, 160, 280). Moreover, M-MDSC
enhanced percentage is also associated with an enhanced frequency of tumor-infiltrating
macrophages after particulate β-glucan treatment. From this observation, and the fact that
M-MDSC upon particulate β-glucan treatment lose their suppressive function and convert
to APCs, implying that particulate β-glucan converts M-MDSC to anti-tumor immune cells
despite of their enhanced frequency. That is also reflected by a significant decrease in
tumor growth. In addition, total Gr-1+ CD11b+ cells failed to suppress antigen-specific
CD4+ and CD8+ T cells when co-cultured with particulate β-glucan.
The differential modulation on both MDSC subsets induced by particulate β-glucan was
also shown in its effect on the functions of both subsets. Firstly, we demonstrated that
particulate β-glucan reverses PMN-MDSC suppression, induces respiratory burst and
enhances apoptosis. On the second axis, particulate β-glucan skews the immature
suppressive phenotype of M-MDSC towards a potent APC phenotype that drives the
differentiation of Th1 CD4+ T cells and induces the differentiation of cytotoxic CD8+ T
cells. On a third and most prevalent axis, particulate β-glucan was tested in patients newly
diagnosed with NSCLC as an adjuvant therapy in cancer. This is the first clinical trial with
particulate β-glucan in patients newly diagnosed with NSCLC that have not yet been
subjected to any other treatment. It is important to note that particulate β-glucan is a natural
compound with no reported off target effects, with a low cost and can be administered
orally.
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Particulate β-glucan induced PMN-MDSC respiratory burst early after activation and
largely enhanced PMN-MDSC apoptosis, which positively correlates with the decreased
frequency of PMN-MDSC in tumors and spleens upon particulate β-glucan treatment.
Although ROS have been implied as one of the main mechanisms for T cell suppression
(281) which is regulated by STAT3 activation (179), other reports suggest that PMNMDSC can acquire a tumor cytotoxic phenotype in the absence of TGF-β (161). That goes
in line with what we previously showed that TGF-β mRNA expression is reduced in tumors
of mice treated with particulate β-glucan (49). In addition, activation of neutrophils with
β-glucan, enhanced neutrophil cytotoxicity against Candida albicans (150). Interestingly,
STAT3 phosphorylation levels in PMN-MDSC decreased after dectin-1/Syk activation
with particulate β-glucan that might have led to PMN-MDSC apoptosis, and correlates with
the findings that treatment of splenic Gr-1+CD11b+ from tumor-bearing mice with the
JAK2/STAT3 inhibitor JSI-I24 in vitro for 7 days in the presence of GM-CSF and tumorconditioned medium enhanced cell death compared to untreated cells (282).
Despite several studies reporting the anti-tumor effect of particulate β-glucan through the
activation of innate immune cells and induction of Th1 T cell responses (49, 104, 130),
little is known on the role of particulate β-glucan in the modulation of tumor-associated
macrophages (TAMs), MDSC and regulatory T cells. It is reported that particulate βglucan induces the differentiation of M-MDSC to F4/80+ CD11c+ cells with a decreased
suppressive phenotype (50). However, this study showed that the differentiated F4/80+
CD11c+ cells represent only 8-13% of the gated M-MDSC population cultured for 48 hours
in the presence of GM-CSF. Whereas, Youn et al showed that GM-CSF alone could induce
the expression of CD11c to around 35% and F4/80 to around 60% in splenic M-MDSC at
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day 3 (32). In our study, the differentiation of M-MDSC to potent APC was only induced
when cultured with a pharmaceutical grade particulate β-glucan (Biothera) that contains
>99% β-glucan rather than a less pure particulate β-glucan. It is important to consider that
different compositions of β-glucan particles could highly impact immune cell function
(104). In addition, expression of F4/80 or CD11c surface markers does not necessarily
imply a non-suppressive phenotype, since it has been shown that MDSC do differentiate
to suppressive F4/80+ cells in the tumor microenvironment(283) (39, 154). The increased
frequency of M-MDSC in the tumors of particulate β-glucan treated mice correlates with
a previous report that particulate β-glucan treatment increases the frequencies of F4/80+
and CD11c+ cells in the tumors of treated mice (49) and since particulate β-glucan reduced
tumor growth it implies that the function of these cells would also be skewed towards an
anti-tumor phenotype.
We also demonstrated that dectin-1 receptor signaling is required for the acquisition of Agpresenting function, since M-MDSC from dectin-1 KO mice treated with particulate βglucan for 7 days did not acquire such capability. Although STAT3 phosphorylation has
been shown to be a key mechanism for MDSC-mediated suppression (284) , we found that
activation of STAT3 in M-MDSC did not impact the reversal of suppression and
acquisition of Ag-presenting phenotype, maybe largely due to the shift in the cytokine
profile towards an ‘M1-like’ phenotype with enhanced expression of IL-12, TNF-α, iNOS
and inhibition of TGF-β, in addition to the upregulation of MHC class II, MHC class I and
the costimulatory markers such as CD86 and CD40. However, the Erk inhibitor completely
abrogated the conversion of M-MDSC to APC mediated by particulate β-glucan.
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It has been well documented that MDSC accumulate in different human cancers such as
brain (285, 286), head and neck (287), breast (228), lung cancer (255, 288) and others
(reviewed in (33, 42, 289)). In many of these studies, the accumulation of MDSC in patients
was correlated with poor prognosis. In the current study, newly diagnosed patients with
NSCLC were given particulate β-glucan orally for two weeks. Treated patients had a
significant decrease in the percentage of CD14- HLA-DR-CD11b+CD33+ MDSC in the
peripheral blood. Importantly, these patients were not exposed to any therapy during the
administration of particulate β-glucan, which allowed the sole assessment of particulate βglucan efficacy in patients. In addition, an enhanced trend in IFN-γ production by CD3+
cells and T cell allogeneic responses to CD14+HLA-DR+ and CD14-HLA-DRCD11b+CD33+ cells was observed after treatment. The administration of particulate βglucan adjuvant for only two weeks may not have been enough to modulate APC function
in vivo, however it was sufficient to reduce the percentages of CD14-HLA-DRCD11b+CD33+ MDSC in the peripheral blood.
The expression of arginase I in PMN-MDSC has been reported in NSCLC patients and
correlated with poor prognosis and CD8+ T cell suppression (41, 266). Interestingly, a
cohort of 15 patients had a significant decreased expression of arginase I in PMN from the
peripheral blood while no significant change was reported in the other 20 patients subjected
to particulate β-glucan treatment. The patients with decreased arginase I after particulate
β-glucan had a higher trend in arginase I expression compared to healthy controls before
the treatment. Unlike the other patients, the level of arginase I was comparable to healthy
controls, suggesting that patients’ variable responses to the treatment might have been due
to different stages, tumor sizes, and progression. Nevertheless, this study provides a first
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insight towards introducing particulate β-glucan as an adjuvant therapy against solid
tumors in humans.
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CONCLUSION REMARKS AND FUTURE PERSPECTIVES

Since their discovery in 1999, MDSC became a great focus of researchers. More than 3500
studies have been published containing the key words ‘myeloid suppressor cells’.
However, the definition of MDSC is still elusive. Amidst the many components in the
tumor microenvironment, immune cell functions are being constantly reshaped by tumorderived factors that mainly switch a large portion of myeloid cells to immune suppressors.
Despite numerous studies describing myeloid cells as key players during tumor
development, their origin, markers of suppression and biology in different cancers is
prompted to vast exploration, especially in humans. Our definition of TAM and MDSC
does not reflect their heterogeneity. In the microenvironment pool, the presence of a
spectrum of phenotypes varying between highly suppressive and least suppressive makes
it difficult to specifically target or re-educate these cells. In this line, it becomes of great
importance to identify a specific marker of suppression that distinguishes inflammatory
monocytes/granulocytes from MDSC. In addition, it is still questionable whether all
suppressive cells are immature and whether a signature for immaturity and its relation to
suppression can be identified in the future. In addition, MDSC in humans is still elusive,
especially that humans lack the Gr-1 homolog. The use of generic myeloid markers such
as CD11b and CD33 does not really differentiate myeloid cells with a suppressive
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phenotype from the ones with an anti-tumor phenotype. Therefore, it becomes of great
importance to define master transcriptional factors that regulate immune cell suppression.
The need to redefine the transcriptional factors that regulate immune cell fate has led to the
establishment of large-scale projects such as the Immunological Genome Consortium and
the Human Immunology project consortium. High-throughput data analysis in such
projects started to reshape our understanding of the complex systems governing immune
cell functions in steady-state and disease onset in mice and humans. It would be of great
significance to establish large-scale studies to define the phenotype of the myeloid cell
compartments in the tumor tissue and peripheral blood in a large cohort of patients with
different types of cancer to elucidate the role of myeloid cells and further define the
transcriptional factors that regulate their suppressive phenotype. More studies using the
yeast-one hybrid system approach and a large-set screening of different cDNA libraries
might be needed to further narrow down key transcriptional factors regulating MDSC
suppression.
More than a century after Coley’s vaccine, cancer immunotherapy has reached its golden
age. The list of immunotherapies approved by the FDA has significantly increased over the
last decade. Monoclonal antibodies such as anti-CTLA-4, anti-PD1 and anti-CD20 have
been widely introduced in cancer therapy, and CAR (chimeric antigen receptor) T cell
therapy with its different versions has also made its way to the clinic. Emphasizing that
targeting tumor cells with chemotherapy is not the only key to eradicate tumors, but reeducating immune cells, and blocking suppressive checkpoints is proven to be a better way
to fight tumor. The formulation of cancer vaccines with adjuvants is well described to help
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providing ‘signal 3’ in antigen-specific adaptive immune responses. The study of better
vehicles for cancer vaccines is being extensively studied. An ‘ideal adjuvant’ is generally
described as having no off-target effects, promotes priming of antigen-specific immune
cell responses and does not cause any associated immune cell suppression. In this study,
we demonstrated that particulate β-glucan, a natural compound with no reported off-target
effects, has the ability to reverse MDSC suppression in mice, and reduce their frequency
in the peripheral blood in patients with NSCLC, suggesting that particulate β-glucan might
be a strong candidate to be used in combination with other immunotherapies. Overall this
study, with its different dimensions, provides evidence that MDSC can be re-educated to
acquire an anti-tumor phenotype.
This study has answered many questions but also opened the doors to the establishment of
many projects in the future to further delineate the transcriptional regulators that define the
acquisition of antigen-presenting function in M-MDSC, the metabolomic enzymes and
metabolites that maybe activated upon dectin-1 activation in MDSC subsets, the effect of
dectin-1 activation on MDSC-mediated tumor cell metastasis, the effect of particulate βglucan on the exosome profile from MDSC and how that might shape tumor cell responses,
and many other questions of great importance that still need to be elucidated to allow the
development of new therapeutic strategies2.

This work was supported by the NIH R01CA150947 P01CA163223 (to J. Y.), the
Kentucky Lung Cancer Research Program, and the American Cancer Society Grant (to C.
D). And Fulbright Scholarship (to SH Albeituni).
2

117

REFERENCES

1.
Marraffini LA, Sontheimer EJ. CRISPR interference: RNA-directed adaptive immunity
in bacteria and archaea. Nature reviews Genetics. 2010;11:181-90.
2.
Thomas CM, Nielsen KM. Mechanisms of, and barriers to, horizontal gene transfer
between bacteria. Nature reviews Microbiology. 2005;3:711-21.
3.
Lanier LL, Sun JC. Do the terms innate and adaptive immunity create conceptual
barriers? Nature reviews Immunology. 2009;9:302-3.
4.
Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of
cytomegalovirus by activating and inhibitory NK cell receptors. Science (New York, NY).
2002;296:1323-6.
5.
Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature.
2009;457:557-61.
6.
Dokun AO, Kim S, Smith HR, Kang HS, Chu DT, Yokoyama WM. Specific and
nonspecific NK cell activation during virus infection. Nature immunology. 2001;2:951-6.
7.
Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology.
Cold Spring Harbor symposia on quantitative biology. 1989;54 Pt 1:1-13.
8.
Medzhitov R, Janeway CA, Jr. On the semantics of immune recognition. Research in
immunology. 1996;147:208-14.
9.
Janeway CA, Jr. Pillars article: approaching the asymptote? Evolution and revolution in
immunology. Cold spring harb symp quant biol. 1989. 54: 1-13. Journal of immunology
(Baltimore, Md : 1950). 2013;191:4475-87.
10.
Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLRinduced chromatin modifications. Nature. 2007;447:972-8.
11.
Alvarez-Errico D, Vento-Tormo R, Sieweke M, Ballestar E. Epigenetic control of
myeloid cell differentiation, identity and function. Nature reviews Immunology. 2015;15:7-17.
12.
Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F, et al.
Epigenetic programming of monocyte-to-macrophage differentiation and trained innate
immunity. Science (New York, NY). 2014;345:1251086.
13.
Ifrim DC, Quintin J, Joosten LA, Jacobs C, Jansen T, Jacobs L, et al. Trained immunity
or tolerance: opposing functional programs induced in human monocytes after engagement of
various pattern recognition receptors. Clinical and vaccine immunology : CVI. 2014;21:534-45.
14.
Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and
HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New
York, NY). 2014;345:1250684.
15.
Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and
implications to cancer immunotherapy. Annals of the New York Academy of Sciences.
2013;1284:1-5.
16.
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in
cancer suppression and promotion. Science (New York, NY). 2011;331:1565-70.
17.
Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer
regression antigens. Immunology today. 1997;18:175-82.

118

18.
Maier T, Holda JH, Claman HN. Murine natural suppressor cells in the newborn, in bone
marrow, and after cyclophosphamide. Genetic variations and dependence on IFN-gamma. Journal
of immunology (Baltimore, Md : 1950). 1989;143:491-8.
19.
Schmidt-Wolf IG, Dejbakhsh-Jones S, Ginzton N, Greenberg P, Strober S. T-cell subsets
and suppressor cells in human bone marrow. Blood. 1992;80:3242-50.
20.
Angulo I, Rodriguez R, Garcia B, Medina M, Navarro J, Subiza JL. Involvement of nitric
oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-gamma. Journal
of immunology (Baltimore, Md : 1950). 1995;155:15-26.
21.
Angulo I, Rullas J, Campillo JA, Obregon E, Heath A, Howard M, et al. Early myeloid
cells are high producers of nitric oxide upon CD40 plus IFN-gamma stimulation through a
mechanism dependent on endogenous TNF-alpha and IL-1alpha. European journal of
immunology. 2000;30:1263-71.
22.
Wright MA, Wiers K, Vellody K, Djordjevic D, Young MR. Stimulation of immune
suppressive CD34+ cells from normal bone marrow by Lewis lung carcinoma tumors. Cancer
immunology, immunotherapy : CII. 1998;46:253-60.
23.
Jaffe ML, Arai H, Nabel GJ. Mechanisms of tumor-induced immunosuppression:
evidence for contact-dependent T cell suppression by monocytes. Molecular medicine
(Cambridge, Mass). 1996;2:692-701.
24.
Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, et al.
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive
population of Mac-1+/Gr-1+ cells. Journal of immunology (Baltimore, Md : 1950).
1998;161:5313-20.
25.
Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, et al. Unopposed
production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell
responses by dysregulating antigen-presenting cell maturation. Journal of immunology
(Baltimore, Md : 1950). 1999;162:5728-37.
26.
Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, et al. Identification of
a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T
cells. Blood. 2000;96:3838-46.
27.
Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice
inhibit primary T cell activation induced through CD3/CD28 costimulation. Journal of
immunology (Baltimore, Md : 1950). 2000;165:779-85.
28.
Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, et al.
The terminology issue for myeloid-derived suppressor cells. Cancer research. 2007;67:425;
author reply 6.
29.
Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A,
Deshpande C, et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human
lung cancer. J Clin Invest. 2014;124:5466-80.
30.
Quatromoni JG, Singhal S, Bhojnagarwala P, Hancock WW, Albelda SM, Eruslanov E.
An optimized disaggregation method for human lung tumors that preserves the phenotype and
function of the immune cells. Journal of leukocyte biology. 2015;97:201-9.
31.
Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin
A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations
with distinct T cell-suppressive activity. Blood. 2008;111:4233-44.

119

32.
Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor
cells in tumor-bearing mice. Journal of immunology (Baltimore, Md : 1950). 2008;181:5791-802.
33.
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells
by tumours. Nature reviews Immunology. 2012;12:253-68.
34.
Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA.
Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in
patients with melanoma. Clinical cancer research : an official journal of the American
Association for Cancer Research. 2012;18:5212-23.
35.
Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, et al. STAT3
regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest.
2013;123:1580-9.
36.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from
immunosurveillance to tumor escape. Nature immunology. 2002;3:991-8.
37.
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annual review
of immunology. 2004;22:329-60.
38.
Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune
system. Nature reviews Immunology. 2009;9:162-74.
39.
Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1alpha regulates
function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
The Journal of experimental medicine. 2010;207:2439-53.
40.
Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, et al. Epigenetic
silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.
Nature immunology. 2013;14:211-20.
41.
Heuvers ME, Muskens F, Bezemer K, Lambers M, Dingemans AM, Groen HJ, et al.
Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral
blood of NSCLC patients. Lung cancer (Amsterdam, Netherlands). 2013;81:468-74.
42.
Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived
suppressor cell heterogeneity in human cancers. Annals of the New York Academy of Sciences.
2014;1319:47-65.
43.
Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune
dysfunction in cancer mediated by immature Gr-1+ myeloid cells. Journal of immunology
(Baltimore, Md : 1950). 2001;166:5398-406.
44.
Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor
cells induce anergy of NK cells through membrane-bound TGF-beta 1. Journal of immunology
(Baltimore, Md : 1950). 2009;182:240-9.
45.
Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote
cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer research.
2008;68:5439-49.
46.
Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloidderived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer
research. 2010;70:68-77.
47.
Kerrigan AM, Brown GD. Syk-coupled C-type lectin receptors that mediate cellular
activation via single tyrosine based activation motifs. Immunological reviews. 2010;234:335-52.

120

48.
Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, et al. Activation
of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature.
2011;472:471-5.
49.
Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, et al. Differential pathways regulating
innate and adaptive antitumor immune responses by particulate and soluble yeast-derived betaglucans. Blood. 2011;117:6825-36.
50.
Tian J, Ma J, Ma K, Guo H, Baidoo SE, Zhang Y, et al. beta-Glucan enhances antitumor
immune responses by regulating differentiation and function of monocytic myeloid-derived
suppressor cells. European journal of immunology. 2013;43:1220-30.
51.
IUPAC Compendium of Chemical Terminology 2nd ed; 1997.
52.
Polysaccharide Nomenclature. European Journal of Biochemistry. 1982;126:439-41.
53.
Deng C, Hu Z, Fu H, Hu M, Xu X, Chen J. Chemical analysis and antioxidant activity in
vitro of a beta-D-glucan isolated from Dictyophora indusiata. International journal of biological
macromolecules. 2012.
54.
Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP) beta-glucan in
conjunction with antitumour monoclonal antibodies to treat cancer. Expert opinion on biological
therapy. 2005;5:691-702.
55.
Kim HJ, White PJ. In Vitro Digestion Rate and Estimated Glycemic Index of Oat Flours
from Typical and High beta-Glucan Oat Lines. Journal of agricultural and food chemistry. 2012.
56.
Tanioka A, An WW, Kuge T, Tsubaki K, Nakaya K. Barley low molecular weight betaglucan potently induces maturation of mouse dendritic cells. Anticancer research. 2011;31:164751.
57.
Skov J, Kania PW, Holten-Andersen L, Fouz B, Buchmann K. Immunomodulatory
effects of dietary beta-1,3-glucan from Euglena gracilis in rainbow trout (Oncorhynchus mykiss)
immersion vaccinated against Yersinia ruckeri. Fish & shellfish immunology. 2012.
58.
Monteiro MA, Slavic D, St Michael F, Brisson JR, MacInnes JI, Perry MB. The first
description of a (1--> 6)-beta-D-glucan in prokaryotes: (1 --> 6)-beta-D-glucan is a common
component of actinobacillus suis and is the basis for a serotyping system. Carbohydrate research.
2000;329:121-30.
59.
Delmer DP. CELLULOSE BIOSYNTHESIS: Exciting Times for A Difficult Field of
Study. Annual review of plant physiology and plant molecular biology. 1999;50:245-76.
60.
Glaser L. The synthesis of cellulose in cell-free extracts of Acetobacter xylinum. The
Journal of biological chemistry. 1958;232:627-36.
61.
Ross P, Mayer R, Benziman M. Cellulose biosynthesis and function in bacteria.
Microbiological reviews. 1991;55:35-58.
62.
Cabib E, Blanco N, Arroyo J. Presence of a large beta(1-3)glucan linked to chitin at the
Saccharomyces cerevisiae mother-bud neck suggests involvement in localized growth control.
Eukaryotic cell. 2012;11:388-400.
63.
Arellano-Reynoso B, Lapaque N, Salcedo S, Briones G, Ciocchini AE, Ugalde R, et al.
Cyclic beta-1,2-glucan is a Brucella virulence factor required for intracellular survival. Nature
immunology. 2005;6:618-25.
64.
Nett J, Lincoln L, Marchillo K, Massey R, Holoyda K, Hoff B, et al. Putative role of
beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrobial agents and chemotherapy.
2007;51:510-20.
65.
Sinskey; SJCKRAJ, inventor Massachussets Institute of Technology, Cambridge, Mass.,
assignee. Glucan compositions and process preparations thereof. United States. 1989.
66.
Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180
by polysaccharides from Lentinus edodes (Berk.) sing. Nature. 1969;222:687-8.

121

67.
Chihara G, Hamuro J, Maeda Y, Arai Y, Fukuoka F. Antitumor polysaccharide derived
chemically from natural glucan (pachyman). Nature. 1970;225:943-4.
68.
Amemura A, Hisamatsu M, Harada T. Spontaneous mutation of polysaccharide
production in Alcaligenes faecalis var. myxogenes 10C3. Applied and environmental
microbiology. 1977;34:617-20.
69.
Sasaki T, Abiko N, Sugino Y, Nitta K. Dependence on chain length of antitumor activity
of (1 leads to 3)-beta-D-glucan from Alcaligenes faecalis var. myxogenes, IFO 13140, and its
acid-degraded products. Cancer research. 1978;38:379-83.
70.
Ohno N, Kurachi K, Yadomae T. Antitumor activity of a highly branched (1----3)-betaD-glucan, SSG, obtained from Sclerotinia sclerotiorum IFO 9395. Journal of pharmacobiodynamics. 1987;10:478-86.
71.
Cheung NK, Modak S, Vickers A, Knuckles B. Orally administered beta-glucans
enhance anti-tumor effects of monoclonal antibodies. Cancer immunology, immunotherapy : CII.
2002;51:557-64.
72.
Jamas SO, GR; Easson, D, inventor Alpha Beta Technology, assignee. Glucan delivery
system and adjuvant. USA. 1990.
73.
Li B, Cramer D, Wagner S, Hansen R, King C, Kakar S, et al. Yeast glucan particles
activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk
kinase-dependent pathways. Clinical immunology (Orlando, Fla). 2007;124:170-81.
74.
Jamas SE, D.; Ostroff, GR; , inventor Alpha-Beta Technology, assignee. Method for
producing neutral glucans for pharmaceutical applications. USA patent 5,322,841. 1994.
75.
Jamas SE, D.; Ostroff, GR;, inventor Alpha-Beta Technology Inc., assignee. Glucan
preparation. USA patent 5,622,939. 1997.
76.
Riggi SJ, Di Luzio NR. Identification of a reticuloendothelial stimulating agent in
zymosan. The American journal of physiology. 1961;200:297-300.
77.
Kelly LS, Dobson EL, Finney CR, Hirsch JD. Proliferation of the reticuloendothelial
system in the liver. Am J Physiol. 1960;198:1134-8.
78.
Pillemer L, Schoenberg MD, Blum L, Wurz L. Properdin system and immunity. II.
Interaction of the properdin system with polysaccharides. Science (New York, NY).
1955;122:545-9.
79.
Hourcade DE. Properdin and complement activation: a fresh perspective. Current drug
targets. 2008;9:158-64.
80.
Pillemer L, Blum L, Pensky J, Lepow IH. The requirement for magnesium ions in the
inactivation of the third component of human complement (C'3) by insoluble residues of yeast
cells (zymosan). Journal of immunology (Baltimore, Md : 1950). 1953;71:331-8.
81.
Brade V, Lee GD, Nicholson A, Shin HS, Mayer MM. The reaction of zymosan with the
properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the
classical complement pathway. Journal of immunology (Baltimore, Md : 1950). 1973;111:1389400.
82.
Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, et al. Zymosan enhances
the immune response to DNA vaccine for human immunodeficiency virus type-1 through the
activation of complement system. Immunology. 2001;103:98-105.
83.
Pillemer L, Ross OA. Alterations in serum properdin levels following injection of
Zymosan. Science (New York, NY). 1955;121:732-3.
84.
Nicholson A, Brade V, Lee GD, Shin HS, Mayer MM. Kinetic studies of the formation of
the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of
assembly. Journal of immunology (Baltimore, Md : 1950). 1974;112:1115-23.

122

85.
Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement
activation by binding specific target surfaces and providing a platform for de novo convertase
assembly. Journal of immunology (Baltimore, Md : 1950). 2007;179:2600-8.
86.
Diller IC, Mankowski ZT, Fisher ME. The effect of yeast polysaccharides on mouse
tumors. Cancer research. 1963;23:201-8.
87.
Sherwood ER, Williams DL, McNamee RB, Jones EL, Browder IW, Di Luzio NR. In
vitro tumoricidal activity of resting and glucan-activated Kupffer cells. Journal of leukocyte
biology. 1987;42:69-75.
88.
Morikawa K, Takeda R, Yamazaki M, Mizuno D. Induction of tumoricidal activity of
polymorphonuclear leukocytes by a linear beta-1,3-D-glucan and other immunomodulators in
murine cells. Cancer research. 1985;45:1496-501.
89.
Scaringi L, Marconi P, Boccanera M, Tissi L, Bistoni F, Cassone A. Cell wall
components of Candida albicans as immunomodulators: induction of natural killer and
macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions.
Journal of general microbiology. 1988;134:1265-74.
90.
Suzuki M, Kikuchi T, Takatsuki F, Hamuro J. Curative effects of combination therapy
with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T
cells. Cancer immunology, immunotherapy : CII. 1994;38:1-8.
91.
Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs
of mice. I. Morphology, quantitation, tissue distribution. The Journal of experimental medicine.
1973;137:1142-62.
92.
Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T, Ross GD. The beta-glucanbinding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of
the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Journal
of immunology (Baltimore, Md : 1950). 1999;162:2281-90.
93.
Zimmerman JW, Lindermuth J, Fish PA, Palace GP, Stevenson TT, DeMong DE. A
novel carbohydrate-glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator,
PGG-glucan, and lactosylceramide of human leukocytes. The Journal of biological chemistry.
1998;273:22014-20.
94.
Rice PJ, Kelley JL, Kogan G, Ensley HE, Kalbfleisch JH, Browder IW, et al. Human
monocyte scavenger receptors are pattern recognition receptors for (1-->3)-beta-D-glucans.
Journal of leukocyte biology. 2002;72:140-6.
95.
Ariizumi K, Shen GL, Shikano S, Xu S, Ritter R, 3rd, Kumamoto T, et al. Identification
of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. The
Journal of biological chemistry. 2000;275:20157-67.
96.
Ross GD, Cain JA, Lachmann PJ. Membrane complement receptor type three (CR3) has
lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and
rabbit erythrocytes as well as a receptor for iC3b. Journal of immunology (Baltimore, Md : 1950).
1985;134:3307-15.
97.
Ezekowitz RA, Sim RB, Hill M, Gordon S. Local opsonization by secreted macrophage
complement components. Role of receptors for complement in uptake of zymosan. The Journal of
experimental medicine. 1984;159:244-60.
98.
Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar
specificity and molecular location of the beta-glucan-binding lectin site of complement receptor
type 3 (CD11b/CD18). Journal of immunology (Baltimore, Md : 1950). 1996;156:1235-46.
99.
Xia Y, Ross GD. Generation of recombinant fragments of CD11b expressing the
functional beta-glucan-binding lectin site of CR3 (CD11b/CD18). Journal of immunology
(Baltimore, Md : 1950). 1999;162:7285-93.

123

100.
Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R. The role of membrane
complement regulatory proteins in cancer immunotherapy. Advances in experimental medicine
and biology. 2008;632:159-74.
101.
Driscoll M, Hansen R, Ding C, Cramer DE, Yan J. Therapeutic potential of various betaglucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer
biology & therapy. 2009;8:218-25.
102.
Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, et al. Beta-glucan
functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal
granulocytes as killer cells. Cancer research. 2003;63:9023-31.
103.
Vetvicka V, Thornton BP, Wieman TJ, Ross GD. Targeting of natural killer cells to
mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3
(CD11b/CD18). Journal of immunology (Baltimore, Md : 1950). 1997;159:599-605.
104.
Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, et al. Mechanism by
which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor
monoclonal antibodies in murine tumor models. Journal of immunology (Baltimore, Md : 1950).
2004;173:797-806.
105.
Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer DE, et al. Yeast beta-glucan
amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Sykphosphatidylinositol 3-kinase pathway. Journal of immunology (Baltimore, Md : 1950).
2006;177:1661-9.
106.
Li B, Allendorf DJ, Hansen R, Marroquin J, Cramer DE, Harris CL, et al. Combined
yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated
neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer research.
2007;67:7421-30.
107.
Thivierge M, Stankova J, Rola-Pleszczynski M. Cysteinyl-leukotriene receptor type 1
expression and function is down-regulated during monocyte-derived dendritic cell maturation
with zymosan: involvement of IL-10 and prostaglandins. Journal of immunology (Baltimore, Md
: 1950). 2009;183:6778-87.
108.
Carmona EM, Kottom TJ, Hebrink DM, Moua T, Singh RD, Pagano RE, et al.
Glycosphingolipids Mediate Pneumocystis Cell Wall beta-Glucan Activation of the IL-23/IL-17
Axis in Human Dendritic Cells. American journal of respiratory cell and molecular biology.
2012.
109.
Carmona EM, Lamont JD, Xue A, Wylam M, Limper AH. Pneumocystis cell wall betaglucan stimulates calcium-dependent signaling of IL-8 secretion by human airway epithelial cells.
Respiratory research. 2010;11:95.
110.
Carmona EM, Vassallo R, Vuk-Pavlovic Z, Standing JE, Kottom TJ, Limper AH.
Pneumocystis cell wall beta-glucans induce dendritic cell costimulatory molecule expression and
inflammatory activation through a Fas-Fas ligand mechanism. Journal of immunology
(Baltimore, Md : 1950). 2006;177:459-67.
111.
Evans SE, Hahn PY, McCann F, Kottom TJ, Pavlovic ZV, Limper AH. Pneumocystis
cell wall beta-glucans stimulate alveolar epithelial cell chemokine generation through nuclear
factor-kappaB-dependent mechanisms. American journal of respiratory cell and molecular
biology. 2005;32:490-7.
112.
Evans SE, Kottom TJ, Pagano RE, Limper AH. Primary alveolar epithelial cell surface
membrane microdomain function is required for Pneumocystis beta-glucan-induced inflammatory
responses. Innate immunity. 2012.
113.
Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates
uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol

124

deposition. Proceedings of the National Academy of Sciences of the United States of America.
1979;76:333-7.
114.
Vereschagin EI, van Lambalgen AA, Dushkin MI, Schwartz YS, Polyakov L, Heemskerk
A, et al. Soluble glucan protects against endotoxin shock in the rat: the role of the scavenger
receptor. Shock (Augusta, Ga). 1998;9:193-8.
115.
Dushkin MI, Safina AF, Vereschagin EI, Schwartz YS. Carboxymethylated beta-1,3glucan inhibits the binding and degradation of acetylated low density lipoproteins in macrophages
In Vitro and modulates their plasma clearance In Vivo. Cell Biochemistry and Function.
1996;14:209-17.
116.
Leake DS, May G, Soyombo AA, Nasr-Esfahani MH. The effect of macrophage
stimulation on the uptake of acetylated low-density lipoproteins. Biochimica et biophysica acta.
1989;1005:196-200.
117.
Wang R, Chandawarkar RY. Phagocytosis of fungal agents and yeast via macrophage
cell surface scavenger receptors. The Journal of surgical research. 2010;164:e273-9.
118.
Ohtani K, Suzuki Y, Eda S, Kawai T, Kase T, Keshi H, et al. The membrane-type
collectin CL-P1 is a scavenger receptor on vascular endothelial cells. The Journal of biological
chemistry. 2001;276:44222-8.
119.
Jozefowski S, Yang Z, Marcinkiewicz J, Kobzik L. Scavenger receptors and beta-glucan
receptors participate in the recognition of yeasts by murine macrophages. Inflammation research :
official journal of the European Histamine Research Society [et al]. 2012;61:113-26.
120.
Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature.
2001;413:36-7.
121.
Taylor PR, Brown GD, Reid DM, Willment JA, Martinez-Pomares L, Gordon S, et al.
The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the
monocyte/macrophage and neutrophil lineages. Journal of immunology (Baltimore, Md : 1950).
2002;169:3876-82.
122.
Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, et al.
Dectin-1 is a major beta-glucan receptor on macrophages. The Journal of experimental medicine.
2002;196:407-12.
123.
Reid DM, Montoya M, Taylor PR, Borrow P, Gordon S, Brown GD, et al. Expression of
the beta-glucan receptor, Dectin-1, on murine leukocytes in situ correlates with its function in
pathogen recognition and reveals potential roles in leukocyte interactions. Journal of leukocyte
biology. 2004;76:86-94.
124.
Palma AS, Feizi T, Zhang Y, Stoll MS, Lawson AM, Diaz-Rodriguez E, et al. Ligands
for the beta-glucan receptor, Dectin-1, assigned using "designer" microarrays of oligosaccharide
probes (neoglycolipids) generated from glucan polysaccharides. The Journal of biological
chemistry. 2006;281:5771-9.
125.
Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H, et al. Dectin-1 is
required for beta-glucan recognition and control of fungal infection. Nature immunology.
2007;8:31-8.
126.
Willment JA, Gordon S, Brown GD. Characterization of the human beta -glucan receptor
and its alternatively spliced isoforms. The Journal of biological chemistry. 2001;276:43818-23.
127.
Grunebach F, Weck MM, Reichert J, Brossart P. Molecular and functional
characterization of human Dectin-1. Experimental hematology. 2002;30:1309-15.
128.
Willment JA, Marshall AS, Reid DM, Williams DL, Wong SY, Gordon S, et al. The
human beta-glucan receptor is widely expressed and functionally equivalent to murine Dectin-1
on primary cells. European journal of immunology. 2005;35:1539-47.
129.
Weck MM, Appel S, Werth D, Sinzger C, Bringmann A, Grunebach F, et al. hDectin-1 is
involved in uptake and cross-presentation of cellular antigens. Blood. 2008;111:4264-72.

125

130.
Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, et al. Orally administered particulate
beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in
cancer. Clinical cancer research : an official journal of the American Association for Cancer
Research. 2010;16:5153-64.
131.
Underhill DM, Rossnagle E, Lowell CA, Simmons RM. Dectin-1 activates Syk tyrosine
kinase in a dynamic subset of macrophages for reactive oxygen production. Blood.
2005;106:2543-50.
132.
Rosas M, Liddiard K, Kimberg M, Faro-Trindade I, McDonald JU, Williams DL, et al.
The induction of inflammation by dectin-1 in vivo is dependent on myeloid cell programming and
the progression of phagocytosis. Journal of immunology (Baltimore, Md : 1950). 2008;181:354957.
133.
Wei WC, Su YH, Chen SS, Sheu JH, Yang NS. GM-CSF plays a key role in zymosanstimulated human dendritic cells for activation of Th1 and Th17 cells. Cytokine. 2011;55:79-89.
134.
Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, Peschel C, et al. Card9 controls
a non-TLR signalling pathway for innate anti-fungal immunity. Nature. 2006;442:651-6.
135.
LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, et al.
Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that
produce interleukin 17. Nature immunology. 2007;8:630-8.
136.
Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, et al. SykDependent Cytokine Induction by Dectin-1 Reveals a Novel Pattern Recognition Pathway for C
Type Lectins. Immunity. 2005;22:507-17.
137.
Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et
al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper
memory cells. Nature immunology. 2007;8:639-46.
138.
Chamilos G, Ganguly D, Lande R, Gregorio J, Meller S, Goldman WE, et al. Generation
of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the
induction of T(H)-17 responses. PloS one. 2010;5:e12955.
139.
Kock G, Bringmann A, Held SA, Daecke S, Heine A, Brossart P. Regulation of dectin-1mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand
troglitazone. Blood. 2011;117:3569-74.
140.
Hernanz-Falcon P, Joffre O, Williams DL, Reis e Sousa C. Internalization of Dectin-1
terminates induction of inflammatory responses. European journal of immunology. 2009;39:50713.
141.
Goodridge HS, Simmons RM, Underhill DM. Dectin-1 stimulation by Candida albicans
yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. Journal of
immunology (Baltimore, Md : 1950). 2007;178:3107-15.
142.
Slack EC, Robinson MJ, Hernanz-Falcon P, Brown GD, Williams DL, Schweighoffer E,
et al. Syk-dependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with
zymosan. European journal of immunology. 2007;37:1600-12.
143.
Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Wevers B, Bruijns SC, et al.
Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation
through Raf-1 and Syk. Nature immunology. 2009;10:203-13.
144.
Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative
Induction of Inflammatory Responses by Dectin-1 and Toll-like Receptor 2. The Journal of
experimental medicine. 2003;197:1107-17.
145.
Dillon S, Agrawal S, Banerjee K, Letterio J, Denning TL, Oswald-Richter K, et al. Yeast
zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and
immunological tolerance. The Journal of Clinical Investigation. 2006;116:916-28.

126

146.
Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, et al.
DC activated via dectin-1 convert Treg into IL-17 producers. European journal of immunology.
2008;38:3274-81.
147.
Tian J, Ma J, Wang S, Yan J, Chen J, Tong J, et al. Increased expression of mGITRL on
D2SC/1 cells by particulate beta-glucan impairs the suppressive effect of CD4+CD25+ regulatory
T cells and enhances the effector T cell proliferation. Cellular immunology. 2011;270:183-7.
148.
Taylor PR, Brown GD, Herre J, Williams DL, Willment JA, Gordon S. The role of
SIGNR1 and the beta-glucan receptor (dectin-1) in the nonopsonic recognition of yeast by
specific macrophages. Journal of immunology (Baltimore, Md : 1950). 2004;172:1157-62.
149.
Kankkunen P, Teirila L, Rintahaka J, Alenius H, Wolff H, Matikainen S. (1,3)-betaglucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. Journal of
immunology (Baltimore, Md : 1950). 2010;184:6335-42.
150.
Li X, Utomo A, Cullere X, Choi MM, Milner DA, Jr., Venkatesh D, et al. The betaglucan receptor Dectin-1 activates the integrin Mac-1 in neutrophils via Vav protein signaling to
promote Candida albicans clearance. Cell host & microbe. 2011;10:603-15.
151.
Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid
progenitor that gives rise to all myeloid lineages. Nature. 2000;404:193-7.
152.
Hettinger J, Richards DM, Hansson J, Barra MM, Joschko AC, Krijgsveld J, et al. Origin
of monocytes and macrophages in a committed progenitor. Nature immunology. 2013;14:821-30.
153.
Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, et al. Tumor-induced
tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity.
2010;32:790-802.
154.
Ma G, Pan PY, Eisenstein S, Divino CM, Lowell CA, Takai T, et al. Paired
immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived
suppressor cells. Immunity. 2011;34:385-95.
155.
Varol C, Landsman L, Fogg DK, Greenshtein L, Gildor B, Margalit R, et al. Monocytes
give rise to mucosal, but not splenic, conventional dendritic cells. The Journal of experimental
medicine. 2007;204:171-80.
156.
Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, et al.
Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response.
Journal of immunology (Baltimore, Md : 1950). 2004;172:4410-7.
157.
Ancuta P, Liu KY, Misra V, Wacleche VS, Gosselin A, Zhou X, et al. Transcriptional
profiling reveals developmental relationship and distinct biological functions of CD16+ and
CD16- monocyte subsets. BMC genomics. 2009;10:403.
158.
Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of
monocytes, macrophages, and dendritic cells. Science (New York, NY). 2010;327:656-61.
159.
Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, Punt JA, et al. The
transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of
Ly6C- monocytes. Nature immunology. 2011;12:778-85.
160.
Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, et al. Immune
tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell reports.
2012;2:628-39.
161.
Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumorassociated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer cell. 2009;16:18394.
162.
Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V, et al. Transcriptomic
analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor
cells and normal neutrophils. PloS one. 2012;7:e31524.

127

163.
Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the
nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Journal of
leukocyte biology. 2012;91:167-81.
164.
Raccosta L, Fontana R, Maggioni D, Lanterna C, Villablanca EJ, Paniccia A, et al. The
oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. The
Journal of experimental medicine. 2013.
165.
Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA, et al. Tumor-derived
gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of
immunosenescence. Journal of immunology (Baltimore, Md : 1950). 2013;190:2403-14.
166.
Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating
gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique
toll-like receptor signaling pathway. Immunity. 2007;27:334-48.
167.
Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived
suppressor cell differentiation and function. Trends in immunology. 2011;32:19-25.
168.
Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocytemacrophage colony-stimulating factor-producing vaccines impair the immune response through
the recruitment of myeloid suppressor cells. Cancer research. 2004;64:6337-43.
169.
Pan PY, Wang GX, Yin B, Ozao J, Ku T, Divino CM, et al. Reversion of immune
tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development
by blockade of stem-cell factor function. Blood. 2008;111:219-28.
170.
Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes
tumor progression by inducing myeloid-derived suppressor cells. Cancer research. 2007;67:450713.
171.
Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, et al.
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. The Journal of
experimental medicine. 2005;202:931-9.
172.
Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular
endothelial growth factor inhibits the development of dendritic cells and dramatically affects the
differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-66.
173.
Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced
inflammation in the tumor microenvironment delays the accumulation of myeloid-derived
suppressor cells and limits tumor progression. Cancer research. 2007;67:10019-26.
174.
Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I
production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor
expression and antigen-specific T-cell responses. Cancer research. 2004;64:5839-49.
175.
Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte
cell-cycle progression. Blood. 2007;109:1568-73.
176.
Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, et al. Fas-induced
caspase denitrosylation. Science (New York, NY). 1999;284:651-4.
177.
Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide
regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. Journal
of immunology (Baltimore, Md : 1950). 1998;160:5729-34.
178.
Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel
group of damage-associated molecular pattern molecules. Journal of leukocyte biology.
2007;81:28-37.
179.
Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism
regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. Journal of
immunology (Baltimore, Md : 1950). 2009;182:5693-701.

128

180.
Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid
cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008;118:3367-77.
181.
Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, et al.
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent
immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin
Invest. 2010;120:457-71.
182.
Sinha P, Parker KH, Horn L, Ostrand-Rosenberg S. Tumor-induced myeloid-derived
suppressor cell function is independent of IFN-gamma and IL-4Ralpha. European journal of
immunology. 2012;42:2052-9.
183.
Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1+CD115+ immature
myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell
anergy in tumor-bearing host. Cancer research. 2006;66:1123-31.
184.
Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between
myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2
response. Journal of immunology (Baltimore, Md : 1950). 2007;179:977-83.
185.
Centuori SM, Trad M, LaCasse CJ, Alizadeh D, Larmonier CB, Hanke NT, et al.
Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-beta-induced
differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. Journal of
leukocyte biology. 2012;92:987-97.
186.
Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al.
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular
carcinoma via the NKp30 receptor. Hepatology (Baltimore, Md). 2009;50:799-807.
187.
Kang CY, Park YJ, Song B, Kim YS, Kim EK, Lee JM, et al. Tumor microenvironmental
conversion of natural killer cells into myeloid-derived suppressor cells. Cancer research. 2013.
188.
Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al. Chemokine nitration
prevents intratumoral infiltration of antigen-specific T cells. The Journal of experimental
medicine. 2011;208:1949-62.
189.
De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, et al. Nitroaspirin
corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer
vaccination. Proceedings of the National Academy of Sciences of the United States of America.
2005;102:4185-90.
190.
Liu L, Li H, Underwood T, Lloyd M, David M, Sperl G, et al. Cyclic GMP-dependent
protein kinase activation and induction by exisulind and CP461 in colon tumor cells. The Journal
of pharmacology and experimental therapeutics. 2001;299:583-92.
191.
Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, et al. Sildenafil and
vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of Bchronic lymphocytic leukemia cells. Blood. 2003;101:265-9.
192.
Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor
cell function. The Journal of experimental medicine. 2006;203:2691-702.
193.
Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, et al. Chronic
inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity
in transgenic mouse melanoma model. Proceedings of the National Academy of Sciences of the
United States of America. 2011;108:17111-6.
194.
Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, et al. Anti-inflammatory
triterpenoid blocks immune suppressive function of MDSCs and improves immune response in
cancer. Clinical cancer research : an official journal of the American Association for Cancer
Research. 2010;16:1812-23.

129

195.
Fernandez A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, et al. Inhibition of
tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. Journal
of immunology (Baltimore, Md : 1950). 2011;186:264-74.
196.
Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively
eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and
enhances antitumor immune activity. Clinical cancer research : an official journal of the
American Association for Cancer Research. 2005;11:6713-21.
197.
Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in
enhanced T cell-dependent antitumor immunity. Cancer research. 2010;70:3052-61.
198.
Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy
P, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
Cancer research. 2011;71:5101-10.
199.
Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly
inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and
augments expansion of T cells from tumor-bearing mice. International immunopharmacology.
2009;9:900-9.
200.
Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, et al. Metronomic
chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell
immunity in vivo. Cancer immunology, immunotherapy : CII. 2013;62:383-91.
201.
Bunt SK, Mohr AM, Bailey JM, Grandgenett PM, Hollingsworth MA. Rosiglitazone and
Gemcitabine in combination reduces immune suppression and modulates T cell populations in
pancreatic cancer. Cancer immunology, immunotherapy : CII. 2013;62:225-36.
202.
Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, et al. Chemotherapy
delivered after viral immunogene therapy augments antitumor efficacy via multiple immunemediated mechanisms. Molecular therapy : the journal of the American Society of Gene Therapy.
2010;18:1947-59.
203.
Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, et al.
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the
Nlrp3 inflammasome and promotes tumor growth. Nature medicine. 2013;19:57-64.
204.
Levin G, Kariv N, Khomiak E, Raz A. Indomethacin inhibits the accumulation of tumor
cells in mouse lungs and subsequent growth of lung metastases. Chemotherapy. 2000;46:429-37.
205.
Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial
cells in vivo. Cancer research. 2002;62:625-31.
206.
Tsubouchi Y, Mukai S, Kawahito Y, Yamada R, Kohno M, Inoue K, et al. Meloxicam
inhibits the growth of non-small cell lung cancer. Anticancer research. 2000;20:2867-72.
207.
Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, et
al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
Cancer research. 2011;71:2664-74.
208.
Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG,
et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of
myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC
cancer. 2010;10:464.
209.
Eruslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S. Pivotal Advance: Tumormediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by
altering intracellular PGE(2) catabolism in myeloid cells. Journal of leukocyte biology.
2010;88:839-48.

130

210.
Obermajer N, Kalinski P. Generation of myeloid-derived suppressor cells using
prostaglandin E2. Transplantation research. 2012;1:15.
211.
Mao Y, Poschke I, Wennerberg E, Pico de Coana Y, Egyhazi Brage S, Schultz I, et al.
Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype
through COX-2-Dependent Mechanisms. Cancer research. 2013;73:3877-87.
212.
George S. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of
gastrointestinal stromal tumor. Current oncology reports. 2007;9:323-7.
213.
Illmer T, Ehninger G. FLT3 kinase inhibitors in the management of acute myeloid
leukemia. Clinical lymphoma & myeloma. 2007;8 Suppl 1:S24-34.
214.
Roskoski R, Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis
inhibitor. Biochemical and biophysical research communications. 2007;356:323-8.
215.
Rajendra R, Pollack SM, Jones RL. Management of gastrointestinal stromal tumors.
Future oncology (London, England). 2013;9:193-206.
216.
Vazquez S, Leon L, Fernandez O, Lazaro M, Grande E, Aparicio L. Sunitinib: the first to
arrive at first-line metastatic renal cell carcinoma. Advances in therapy. 2012;29:202-17.
217.
Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, et al. Long-Term
Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma. Clinical genitourinary
cancer. 2013.
218.
Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of
tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor
microenvironment for immune-based cancer therapies. Cancer research. 2009;69:2514-22.
219.
Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3
induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer
research. 2009;69:2506-13.
220.
Abe F, Younos I, Westphal S, Samson H, Scholar E, Dafferner A, et al. Therapeutic
activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. International
immunopharmacology. 2010;10:140-5.
221.
Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, et al. Sunitinib facilitates
the activation and recruitment of therapeutic anti-tumor immunity in concert with specific
vaccination. International journal of cancer Journal international du cancer. 2011;129:2158-70.
222.
Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, et al. Direct and differential
suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally
constrained. Cancer research. 2010;70:3526-36.
223.
Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor
escape from sunitinib mediated anti-angiogenic therapy. International immunopharmacology.
2011;11:856-61.
224.
Panka DJ, Liu Q, Geissler AK, Mier JW. Effects of HDM2 antagonism on sunitinib
resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid
derived suppressor cells. Molecular cancer. 2013;12:17.
225.
Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal
of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clinical cancer
research : an official journal of the American Association for Cancer Research. 2009;15:2148-57.
226.
van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ,
et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+
dendritic cell frequency predicts progression-free survival. Clinical cancer research : an official
journal of the American Association for Cancer Research. 2008;14:5884-92.
227.
Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonatemediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived

131

suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer research.
2007;67:11438-46.
228.
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ.
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage,
metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer
immunology, immunotherapy : CII. 2009;58:49-59.
229.
Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Gorgens A, et al. Vemurafenib
reverses immunosuppression by myeloid derived suppressor cells. International journal of cancer
Journal international du cancer. 2013;133:1653-63.
230.
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets
of genetic alterations in melanoma. The New England journal of medicine. 2005;353:2135-47.
231.
Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, et al. Granulocyte-colony
stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.
Proceedings of the National Academy of Sciences of the United States of America.
2010;107:21248-55.
232.
Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, et al. Bv8 regulates myeloid-celldependent tumour angiogenesis. Nature. 2007;450:825-31.
233.
Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, et al. Inhibition of
colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor
GW2580. Proceedings of the National Academy of Sciences of the United States of America.
2005;102:16078-83.
234.
Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, et
al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating
tumor evasion of antiangiogenic therapy. Blood. 2010;115:1461-71.
235.
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits
inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222-5.
236.
Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta
signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.
Cancer cell. 2008;13:23-35.
237.
Young MR, Wright MA, Vellody K, Lathers DM. Skewed differentiation of bone
marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection
of differentiation toward dendritic cells by 1alpha,25-dihydroxyvitamin D3. International journal
of immunopharmacology. 1999;21:675-88.
238.
Kulbersh JS, Day TA, Gillespie MB, Young MR. 1alpha,25-Dihydroxyvitamin D(3) to
skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells.
Otolaryngology--head and neck surgery : official journal of American Academy of
Otolaryngology-Head and Neck Surgery. 2009;140:235-40.
239.
Walsh JE, Clark AM, Day TA, Gillespie MB, Young MR. Use of alpha,25dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous
cell carcinoma. Human immunology. 2010;71:659-65.
240.
Walker DD, Reeves TD, de Costa AM, Schuyler C, Young MR. Immunological
modulation by 1alpha,25-dihydroxyvitamin D3 in patients with squamous cell carcinoma of the
head and neck. Cytokine. 2012;58:448-54.
241.
Di Rosa M, Malaguarnera G, De Gregorio C, Palumbo M, Nunnari G, Malaguarnera L.
Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cellular
immunology. 2012;280:36-43.
242.
Zhang H, Maric I, Diprima MJ, Khan J, Orentas RJ, Kaplan RN, et al. Fibrocytes
represent a novel MDSC subset circulating in patients with metastatic cancer. Blood. 2013.

132

243.
Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in
patients with advanced breast cancer undergoing chemotherapy with taxanes. British journal of
cancer. 2002;87:21-7.
244.
Young MR, Lathers DM. Combination docetaxel plus vitamin D(3) as an immune
therapy in animals bearing squamous cell carcinomas. Otolaryngology--head and neck surgery :
official journal of American Academy of Otolaryngology-Head and Neck Surgery.
2005;133:611-8.
245.
Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel
chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells
in tumor bearers. Clinical cancer research : an official journal of the American Association for
Cancer Research. 2010;16:4583-94.
246.
Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S. Blockade of myeloid-derived
suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine
model of melanoma. Journal of immunology (Baltimore, Md : 1950). 2012;189:5147-54.
247.
Sevko A, Kremer V, Falk C, Umansky L, Shurin MR, Shurin GV, et al. Application of
paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal
mice. Journal of immunotoxicology. 2012;9:275-81.
248.
Michels T, Shurin GV, Naiditch H, Sevko A, Umansky V, Shurin MR. Paclitaxel
promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a
TLR4-independent manner. Journal of immunotoxicology. 2012;9:292-300.
249.
Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, et al.
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and
cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc
breast cancer. Breast cancer research and treatment. 2012;132:215-23.
250.
Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic
leukemic cells in primary culture in response to retinoic acid. Blood. 1981;57:1000-4.
251.
Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-transretinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect
of vaccination. Cancer research. 2003;63:4441-9.
252.
Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of
all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer
research. 2007;67:11021-8.
253.
Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY. The restoration of myeloid-derived
suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid
treatment. International journal of cancer Journal international du cancer. 2012;131:741-51.
254.
Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, et al. All-trans-retinoic
acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer
research. 2006;66:9299-307.
255.
Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of
myeloid-derived suppressor cells and immune response to cancer vaccine in patients with
extensive stage small cell lung cancer. Cancer immunology, immunotherapy : CII. 2013;62:90918.
256.
Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, et al. Reversal of
myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008;14:8270-8.
257.
Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, Sandholzer N, et al. CpG
blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clinical

133

cancer research : an official journal of the American Association for Cancer Research.
2011;17:1765-75.
258.
Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, et al. Curcumin induces the differentiation
of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related
tumor growth. Cancer prevention research (Philadelphia, Pa). 2012;5:205-15.
259.
Saijo S, Fujikado N, Furuta T, Chung SH, Kotaki H, Seki K, et al. Dectin-1 is required
for host defense against Pneumocystis carinii but not against Candida albicans. Nature
immunology. 2007;8:39-46.
260.
Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric analysis of
the granulocyte respiratory burst: a comparison study of fluorescent probes. Journal of
immunological methods. 1995;178:89-97.
261.
Walrand S, Valeix S, Rodriguez C, Ligot P, Chassagne J, Vasson MP. Flow cytometry
study of polymorphonuclear neutrophil oxidative burst: a comparison of three fluorescent probes.
Clinica chimica acta; international journal of clinical chemistry. 2003;331:103-10.
262.
Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance
induced by bone marrow-derived immature myeloid cells. Journal of immunology (Baltimore,
Md : 1950). 2005;175:4583-92.
263.
Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors
induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J
Clin Invest. 2006;116:2777-90.
264.
Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived
suppressor cells. Cancer research. 2008;68:2561-3.
265.
Huang A, Zhang B, Wang B, Zhang F, Fan KX, Guo YJ. Increased CD14(+)HLA-DR (/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response
to chemotherapy in non-small cell lung cancer patients. Cancer immunology, immunotherapy :
CII. 2013;62:1439-51.
266.
Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, et al. Population alterations of
L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+
myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage nonsmall cell lung cancer. Journal of cancer research and clinical oncology. 2010;136:35-45.
267.
Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation.
Cell.144:646-74.
268.
Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, et al. Tumor
microenvironment complexity: emerging roles in cancer therapy. Cancer research. 2012;72:247380.
269.
Stout RD, Watkins SK, Suttles J. Functional plasticity of macrophages: in situ
reprogramming of tumor-associated macrophages. Journal of leukocyte biology. 2009;86:1105-9.
270.
Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate
immunity: macrophages, mast cells and neutrophils. Nature immunology. 2011;12:1035-44.
271.
Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of macrophage
plasticity, diversity, and polarization: lessons and open questions. Arteriosclerosis, thrombosis,
and vascular biology. 2013;33:1478-83.
272.
Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptomebased network analysis reveals a spectrum model of human macrophage activation. Immunity.
2014;40:274-88.
273.
Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic
lymphocytes. Immunology. 1970;18:723-37.
274.
Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell.
2000;101:455-8.

134

275.
Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T
cells. Advances in immunology. 2010;108:111-65.
276.
Shurin GV, Ouellette CE, Shurin MR. Regulatory dendritic cells in the tumor
immunoenvironment. Cancer immunology, immunotherapy : CII. 2012;61:223-30.
277.
Fu B, Tian Z, Wei H. Subsets of human natural killer cells and their regulatory effects.
Immunology. 2014;141:483-9.
278.
Tedder TF. B10 cells: a functionally defined regulatory B cell subset. Journal of
immunology (Baltimore, Md : 1950). 2015;194:1395-401.
279.
Staron MM, Gray SM, Marshall HD, Parish IA, Chen JH, Perry CJ, et al. The
transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of
antiviral CD8(+) T cells during chronic infection. Immunity. 2014;41:802-14.
280.
Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, et al.
Origins of tumor-associated macrophages and neutrophils. Proceedings of the National Academy
of Sciences of the United States of America. 2012;109:2491-6.
281.
Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of
CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen
species. Journal of immunology (Baltimore, Md : 1950). 2004;172:989-99.
282.
Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI.
Regulation of dendritic cell differentiation and antitumor immune response in cancer by
pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and
activators of transcription 3 pathway. Cancer research. 2005;65:9525-35.
283.
Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion
of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor
angiogenesis. Cancer cell. 2004;6:409-21.
284.
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for
STAT3. Nature reviews Cancer. 2009;9:798-809.
285.
Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, et al. Myeloid-derived
suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neurooncology. 2011;13:591-9.
286.
Sippel TR, White J, Nag K, Tsvankin V, Klaassen M, Kleinschmidt-DeMasters BK, et al.
Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular
immune function by targeting arginase I. Clinical cancer research : an official journal of the
American Association for Cancer Research. 2011;17:6992-7002.
287.
Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, et al. Myeloidderived suppressor cells in the peripheral blood of cancer patients contain a subset of immature
neutrophils with impaired migratory properties. Journal of leukocyte biology. 2011;89:311-7.
288.
Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased
production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in
cancer. Journal of immunology (Baltimore, Md : 1950). 2001;166:678-89.
289.
Albeituni SH, Ding C, Yan J. Hampering immune suppressors: therapeutic targeting of
myeloid-derived suppressor cells in cancer. Cancer journal (Sudbury, Mass). 2013;19:490-501.

135

CURRICULUM VITAE
Sabrin Albeituni
Tel: (502 408-5960)
Email: salbeituni@gmail.com
EDUCATION
June 2015: PhD – Microbiology and Immunology - Department of Microbiology and
Immunology University of Louisville - Louisville, KY (mentor
Dr. Jun Yan)
Aug 2012: M.S. Immunology - Department of Microbiology and Immunology University of Louisville - Louisville, KY (mentor Dr. Jun Yan)
Jun 2008: B.S. Biology - Department of Biology and Biochemistry - Birzeit University West Bank, the Palestinian Territories
RESEARCH EXPERIENCE
Nov 2015- present: Postdoctoral Research Associate- St. Jude Children’s Research
Hospital- Department of Oncology- Memphis, USA
TEACHING EXPERIENCE
Aug 2008-Aug 2010: Teaching assistant- Birzeit University- Department of Biology and
Biochemistry- West Bank, the Palestinian Territories
PROFESSIONAL MEMBERSHIPS AND COMMITTEES
2015: American Association of Immunologists
2014-2015: Graduate Student Council Representative - University of Louisville
2011-2012: Curriculum Committee Representative - University of Louisville
2007-2008: Science Council Representative - Birzeit University
HONORS AND AWARDS
May 2015: American Association of Immunologists Trainee Abstract Award
Sep 2014: Condict Moore Graduate Student Research Award -First Place - James
Graham Brown Cancer
Center Annual Research Retreat
Sep 2013: Michael K. Tanner Award for Excellence in Graduate Student Sciences University of Louisville
2010-2012: Fulbright Scholarship

136

ENTERPRENEURSHIP SEMINARS
1- Fulbright Global Food Security Seminar. Penn State University, PA. Feb 2012.
2- Fulbright Enrichment Seminar: From Lab to Market. Cambridge, MA. May 2011.
VOLUNTEER WORK
2013: Volunteer at Kosair Children's Hospital and Norton Healthcare - Louisville, KY.
PUBLICATIONS
Published articles
1- Hudson SV, Huang JS, Yin W, Albeituni S, Rush J, Khanal A, Yan J, Ceresa BP,

2-

3-

4-

5-

Frieboes HB, McNally LR . Targeted noninvasive imaging of EGFR-expressing
orthotopic pancreatic cancer using multispectral optoacoustic tomography. Cancer
Res. 2014;74:6271-9. PMID:25217521.
Albeituni SH, Ding C, Yan J. Hampering immune suppressors: therapeutic targeting
of myeloid-derived suppressor cells in cancer. Cancer J. 2013;19:490-501.
PMID:24270348.
Albeituni SH, Yan J. The effects of beta-glucans on dendritic cells and implications
for cancer therapy. Anti-cancer Agents Med Chem. 2013;13:689-98.
PMID:23092290.
Liu M, Luo F, Ding C, Albeituni S, Hu X, Ma Y, Cai Y, McNally L, Sanders MA,
JainD, Kloecker G, Bousamra M 2nd, Zhang H, Higashi RM, Lane A, Fan TM, Yan J.
Dectin-1 Activation by a Natural Product β-Glucan Converts Immunosuppressive
Macrophages into an M1-like Phenotype with Tumoricidal Activity. J Immunol.
2015;195(10):5055-65. PMID:26453753.
Yaddanapudi K, Rendon B, Lamont G, Kim EJ, Al Rayyan N, Richie J, Albeituni S,
Waigel S, Wise A, Mitchell R. MIF is necessary for late-stage melanoma patient
MDSC immune suppression and differentiation. Cancer Immunol Res. (In Press).

Articles under review
1- Albeituni S., Liu M, Ding C, Hu X, Luo F, Kloecker G, Bousamara II M, Zhang H,
Yan J. Dectin-1 Activation Subverts the Suppression of Myeloid-derived Suppressor
Cells by Inducing PMN-MDSC Apoptosis and M-MDSC Differentiation to APC in
Cancer. J Immunol. Submitted on Aug 17, 2015.
Book Chapters
1- Pervaiz Dar, Sabrin Albeituni: MHC tetramer assay for analysis of virus-specific T
cells. Essential Skills in Veterinary Virology. Nov, 2013.
ABSTRACTS AND PRESENTATIONS
Oral Presentations
1- Dectin-1 activation subverts the suppression of myeloid-derived suppressor cells by
inducing PMN-MDSC apoptosis and monocytic MDSC differentiation to potent
137

antigen-presenting cells in cancer. American Association of Immunologists annual
meeting, New Orleans, LA. May 12, 2015.
2- Particulate beta-glucan modulates myeloid-derived suppressor cells (MDSC) activity
in tumor-bearing mice and lung cancer patients. Invited speaker at the Institute of
Cellular Therapeutics. Louisville, KY. May 27, 2014.
Poster presentations
1- Albeituni S, Liu M, Ding C, Hu X, Luo F, Yan J. Dectin-1 activation subverts the
suppression of myeloid-derived suppressor cells by inducing PMN-MDSC apoptosis
and monocytic MDSC differentiation to potent antigen-presenting cells in cancer.
American Association of Immunologists annual meeting, New Orleans, LA. May
2015. American Association of Immunologists Trainee Award.
2- Albeituni S, Ding C, Liu M, Hu X, and Luo F, Yan J. Dectin-1 activation with
whole-glucan particles subverts suppression of myeloid-derived suppressor cells in
cancer. Brown Cancer Center annual retreat, Louisville, KY. Oct 2014. First Place
Graduate Student Research Award.
3- Albeituni S, Ding C, Liu M, Hu X, Luo F, Yan J. Particulate beta-glucan modulates
myeloid-derived suppressor cells (MDSC) activity in tumor-bearing mice and lung
cancer patients. American Association of Immunologists annual meeting. Pittsburgh,
PA. May 2014.
4- Albeituni S, Ding C, Liu M, Hu X, Yan J. Whole-glucan particles modulate myeloidderived suppressor cells in cancer. Research Louisville. Louisville, KY. Sep 2013.
First Place Michael K. Tanner Award.
5- Albeituni S, Ding C, Liu M, Hu X, Luo F, Fleming C, Yan J. Whole-Glucan
Particles (WGP) Modulate Myeloid-Derived Suppressor Cells (MDSC) in Cancer.
Brown Cancer Center annual retreat. Louisville, KY. Oct 2013.
6- Albeituni S, Ding C, Liu M, Hu X, and Yan J. Effects of Whole Glucan Particles
(WGP) on myeloid-derived suppressor cells (MDSC) in tumor-bearing animals.
Brown Cancer Center annual retreat, Louisville, KY. Oct 2012.
LABORATORY SKILLS
In vivo main skills:




Mice: Maintaining mice colonies, breeding, genotyping, handling tumor-bearing
mice, intraperitoneal, intravenous, footpad and subcutaneous injection, blood and
organ collection
In vivo T cell proliferation assays
In vivo imaging

Expert at:






Flow cytometry
Cell sorting from tissues and cell lines: FACS sorting, magnetic beads cell sorting
Cell culture: culture of primary cells, tumor cell lines
Processing of human blood and human tumors for FACS analysis
DNA and RNA isolation: PCR and quantitative RT-PCR
138




ELISA (enzyme-linked immunosorbent assay)
Lymphocyte proliferation assays, mixed-lymphocyte reaction assays, antigen
proliferation assays, antigen-presentation assays

Competent at:



Western blot
Confocal microscopy

Instruments used:




Flow cytometry: FACS Calibur, FACS Canto II
Cell sorting: FACS Aria III, AutoMacs Cell Sorter
In vivo Imaging: Advanced Molecular Imaging (AMI) Systems

139

